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Preface
Alcohol and drug abuse have become major health and social problems
in the United States. Ten million American adults and 3.3 million
youths in the 14 to 17 age range may be problem drinkers.(1) In a
recent survey of high school seniors, nearly two-thirds of a
seniors report illicit drug use at some time in their lives.(2)
A wealth of literature documents that genetic factors play a
significant role in the transmission of at least some forms of
alcohol abuse and alcoholism. Studies in humans and animals further
suggest a genetic influence in individual variations of behavioral
and biological responses, as well as differential organ
sensitivities to the damaging effects of alcohol. The genetic
influence in drug abuse is, however, less well documented. There
are reports suggesting that genetics play a role in the user's
performance after opiate use. Several studies suggest that
preference for morphine is genetically related and that animal
responses to cocaine and morphine also appear to vary with genetic
background.
It is generally agreed that the genetic component in alcohol and
drug abuse is multifactorial and there may be identifiable traits or
markers that can single out individuals at risk. To foster research
in this important area, the National Institute on Drug Abuse (NIDA)
and the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
cosponsored a technical review entitled: "Genetic and Biological
Markers in Drug Abuse and Alcoholism."
This meeting brought together researchers from the alcohol and drug
abuse research communities to discuss the state of knowledge
regarding genetic and biological markers, to identify research gaps,
and to recommend future directions. Topics discussed represented a
multidisciplinary approach ranging from family studies to animal
models and from behavioral traits to gene mapping.
This monograph includes the 10 papers presented at this workshop and
a summary of the presentations, prepared by Dr. Warren Nichols.
Areas in need of additional efforts or further development and
future directions for research recommended by workshop participants
v
are listed in a concluding chapter by the editors. The publication
represents the beginning of a coordinated effort between NIDA and
NIAAA to advance the field of genetic research in substance abuse.
We hope that it will stimulate collaboration among scientists in
various disciplines from both the alcoholism and the drug abuse
research communities.
Monique C. Braude, Ph.D.
National Institute on Drug Abuse
Helen M. Chao, Ph.D.
National Institute on Alcohol
Abuse and Alcoholism
(1) Noble, E.P., ed.: "Third Special Report to the U.S. Congress on
Alcohol and Health." June, 1978. National Institute on Alcohol
Abuse and Alcoholism. DHHS Publication No. (ADM) 79-832.
Rockville, MD: NIAAA, 1979.
(2) Johnston, L.D.; O'Malley, P.M.; and Bachman, J.G.: "Drugs and
American High School Students 1975-1983." National Institute on
Drug Abuse. DHHS Publication No. (ADM) 85-1374. Rockville, MD:
NIDA, 1984.
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Genetic and Biological Markers in
Drug Abuse and Alcoholism:
A Summary
Warren W. Nichols, M.D., Ph.D.
The workshop on "Genetic and Biological Markers in Drug Abuse and
Alcoholism" reported in this monograph was jointly sponsored by
the National Institute on Drug Abuse (NIDA) and the National
Institute on Alcohol Abuse and Alcoholism (NIAAA). It brought
together individuals from both abuse areas with expertise in
clinical research, animal models, and molecular systems. The
aims for examining genetic and biologic markers of substance
abuse were twofold. The first aim was to develop methods for the
use of markers that could predict individuals with a hereditary
predisposition or susceptibility to alcoholism or drug addiction,
as well as predict hereditary alterations that could enhance the
toxic effects of these substances. The second aim was to examine
the use of biologic and genetic parameters to detect damage or
alterations produced by alcohol and drug abuse.
The difficulties encountered in these areas because of imprecision
and variability of diagnostic criteria and classification were
pointed out and discussed several times throughout the meeting.
It was clear that bringing together interdisciplinary groups,
such as those attending this workshop, was one good method of
reducing this variability, and it was also clear that a series
of separate meetings designed to unify diagnostic criteria and
classification would benefit the entire area of drug and alcohol
research. Further problems encountered are produced by the
almost certain heterogeneity and multifactional nature of
individuals abusing drugs and alcohol.
The markers or phenomena that may be of use in recognizing or
detecting alcohol and drug abuse that were discussed at the
meeting included: phenotypic and genotypic areas from behavioral
observations and clinical genetic studies; polymorphisms in
gene products, such as pharmacogenetic differences in metaboliz-
ing enzymes, isoenzyme variations, antigenic markers as blood
groups, and the HLA systems; and DNA polymorphisms detected by
restriction enzyme fragment length differences.
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Strong evidence for a genetic factor or factors in alcoholism
was presented in two clinical research papers by Drs. C. Robert
Cloninger and Marc Schuckit. Both studies reported a marked
increase in the prevalence of alcoholism in a population which
had a first-degree relative that was alcoholic versus the
general population. Various demographic means, including
adoption studies, demonstrated that this was related to a
genetic trait rather than to environmental exposure. However, both
studies agreed that there were multiple genetic and environmental
influences in this complex phenotype. Dr. Cloninger also
reported a large excess of male over female alcoholics in both
the general population and the population with first-degree
alcoholic relatives. These differences appeared to have a
genetic basis and could not be explained by socioenvironmental
factors alone. Similar studies on opiates and other drugs of
abuse are not currently available, but it is believed that
from the alcohol experience similar studies could be
established to determine the role of genetic factors in drug
abuse.
Dr. Arthur Falek presented clinical research studies designed to
examine opiate-induced alterations in chromosomes, DNA repair,
and immunologic functions. Studies of peripheral lymphocytes of
addicts demonstrated a significant increase in the levels of
chromosome aberrations and sister chromatid exchange (SCE)
events. There was also an increased response in these parameters
after treatment with ultraviolet light. Formation of T lympho-
cytes E-rosettes was also reduced in these addicts. Some
recovery of all parameters was observed in long-term methadone
patients and marked individual variation occurred. The large
number of variables in street drug users and the importance of
separating effects of abuse substances from susceptibility to
abuse substances was emphasized by Dr. Falek. He pointed out
that there is at present no study that indicates a genetic
potential to altered response to opiates, and that twins may be
a suitable way to explore this hypothesis if a sufficiently
large addict population is available for study.
Animal models were discussed in separate presentations by Drs.
T.K. Li, Allan Collins, and Louis Shuster. Dr. Li described
his studies on alcoholism using a rat model. By selecting and
breeding rats that had a preference for alcohol over water, Dr.
Li has developed animals that self-administer alcohol by mouth
and achieve pharmacologically significant blood levels for the
pharmacologic effect rather than for the caloric value, taste,
or smell. The ethanol is positively reinforcing and leads to
tolerance and physical dependence. Animals bred for these
characteristics exhibit lower levels of serotonin and 5-hydroxy-
indolacetic acid in various areas of the brain. Other biochemical
and physiologic parameters are being sought with the long-term
goal of eventual human application.
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Drs. Collins and Shuster discussed the use of various strains of
mice in studies of alcohol and drug abuse. They pointed out
that some markers of abuse substances that are of interest may
require the introduction of the substance to initiate the
marker. Also, important markers may be found in tissues not
readily accessible in humans. In both situations, animal models
may overcome these difficulties. The wealth of inbred strains.
recombinant inbred strains, congenic lines, and selectively bred
lines offer excellent starting material for analysis of genetic
predispositions. Marked differences in responses to opiates,
ethanol, and nicotine between C57B1/6 and DBA/2 mice are being
utilized to study differences in receptors, neurotransmitters,
and endogenous opiates. Evidence was cited that high-affinity
receptors are present for opiates but have not been found for
ethanol. Evidence that animals can become addicted to endogenous
opiates based on withdrawal symptoms after naloxone treatment
was also described. Publication of a compendium of quantitative
differences in drug responses of the many inbred lines and mutants
as they are determined would be very helpful to investigators in
this field.
Dr. Vesell's discussion of pharmacogenetic approaches to the
prediction of drug response served as a bridge between the
clinical studies, the animal models, and the molecular studies.
He described genetic factors subject to environmental modifica-
tions that are capable of producing variations up to fortyfold
in drug clearance, plasma drug half-life, and steady-state blood
drug concentrations. Several hereditary conditions with unusual
drug reactions based on pharmacogenetic differences were described,
as were associations with phenotypic markers such as the HLA
type. Dr. Vesell demonstrated mistakes in evaluating genetic
metabolic polymorphisms in family studies if only the parent
compound is evaluated in the absence of metabolic products.
Dr. Robert S. Sparkes listed the variety of polymorphic gene
markers that are available for studying disease association and
genetic linkage. Association refers to a close relationship
between a trait or a disease and a specific allelic variant
revealed by the study of unrelated individuals, and it is probably
important in the pathogenesis of the disease or trait. Genetic
linkage refers to the physical location of genes close to each
other on the same chromosome and requires family studies for
elucidation. Linkage studies can be used to determine which
members of an at-risk family possess a gene which has been
proven to be linked to increased susceptibility to a disease
state, while association studies may be important in determining
whether a specific genetic variant is associated with a reaction
to alcohol or another drug. Of the various polymorphic gene
markers available, Dr. Sparkes pointed out the several advantages
of DNA restriction fragment length polymorphisms (RFLP). These
include the fact that the gene or genes in the polymorphic DNA
fragments need not be expressed or even identified, and that all
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regions of the genome can be covered rather than the approximately
20% that occurs with other phenotypic markers. This means that
any gene under question should be linkable.
Dr. Moyra Smith-Wright described the preparation of a cDNA clone
for the alcohol dehydrogenase 1 gene (ADH1) from messenger RNA
for the polypeptide gene product. This probe was used to study
the closely homologous three class I ADH genes for polymorphism
at the DNA level. The results suggest that polymorphisms occur
in at least two of the ADH genes and that the polymorphisms are
heritable. By the use of somatic cell hybrids, it has also been
possible to map these genes to the long arm of chromosome 4.
There are indications that the fetal alcohol syndrome has genetic
factors that may be approachable through these polymorphisms in
genes coding for metabolic enzymes and that this may be a good
starting point for work with these probes.
All in all, this workshop was very productive with excellent
interaction between the various interdisciplinary groups. It is
certainly time, and this is an excellent method to select well-
thought-out studies in new areas that may contribute to both
prevention and treatment of these large problems.
AUTHOR
Warren W. Nichols, M.D., Ph.D.
Merck Sharp & Dohme
Research Laboratory
West Point, Pennsylvania 19486
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Polymorphic Gene Marker Studies
Robert S. Sparkes, M.D.
INTRODUCTION
Common genetic variations are called polymorphisms and refer to
genetic traits for which at least two allelic variants occur with
a frequency which cannot be attributed to recurrent mutation alone;
therefore, each variant usually occurs with a frequency greater
than 2%. Man, being a diploid organism, has only two alleles at
each locus, but in a population of individuals there may be many
alleles at a locus. The biological significance of many of these
polymorphisms remains to be determined.
Currently available polymorphic genetic markers can be grouped
into phenotypic and DNA markers. The phenotypic markers include
red blood cell antigens, red blood cell isoenzymes, serum proteins,
and HLA antigens. The polymorphic variants at the DNA level are
called restriction fragment length polymorphisms (RFLPs).
APPLICATIONS OF POLYMORPHIC GENE MARKERS
Polymorphic genetic variation has applications in a number of
areas, but basically they afford means to identify or distinguish
the presence or absence of specific genetic alleles. This varia-
tion can be used for individual identification, such as in forensic
studies where blood stains are compared with fresh blood from a
known person. The oldest application of genetic polymorphic studies
in the laboratory is with blood transfusions in which there is
matching between donor and recipient for polymorphic red blood cell
antigens, especially in the ABO and the Rh systems. Similar appli-
cation is made in tissue transplantation using the HLA polymorphic
variation. In bone marrow transplantation, the other polymorphic
markers, such as isoenzymes, can be used to identify the presence
of donor cells in a recipient following a transplant; this is based
upon differences in any of the polymorphic markers between donor
and recipient. These polymorphisms are also used for paternity
evaluation in which these markers are compared between the child,
its mother, and the putative father, searching for evidence that
there is a genetic trait that the child could not have received from
the man in question. Such information is also needed in genetic
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linkage studies (see below). Isoensyme polymorphisms have been
used to demonstrate cross-contamination of tissue culture cell lines.
It is not uncommon to find a mixup in cultures and that the investi-
gator is not working with the expected culture: isoenzyme studies
have demonstrated that upwards of 30% of such cultures are of an un-
expected type. Major applications have also been made to the study
of human gene mapping using polymorphic traits in linkage analysis.
Finally, studies have been made to evaluate possible associations of
diseases or other traits with specific allelic types, particularly
with the ABO blood group and the HLA white blood cell system.
GENETIC LINKAGE
Human gene mapping has made major advances in recent years. This
has largely been achieved through the use of interspecific somatic
cell hybridization. This approach is based upon the nonrandom loss
of human chromosomes from the somatic cell hybrids formed between
established rodent cell lines and human cells. A correlation is
made between which human genes and which human chromosomes are pres-
ent in a panel of different hybrid clones. Although each clone
usually has more than one human chromosome, the different clones are
chosen so that the total panel will permit assignment of a specific
gent to a specific chromosome. This technique can also be used to
regionally map genes on a chromosome by starting with human cells
which contain a chromosome rearrangement, usually a translocation.
The correlation is then made between the gene in question and that
part of a chromosome which remains in the somatic cell hybrid. One
of the advantages of this technique is that it does not depend upon
polymorphism for the gene which is being mapped. Much of the past
work with somatic cell hybrids has utilized species differences in
enzymes which can be seen on electrophoresis or isoelectric focusing.
In contrast to the somatic cell hybridization approach, human gent
mapping through linkage analysis does depend on genetic polymorphism.
With genetic linkage, one measures gene map distance between two genes
as reflected in the number of cross-overs which occur in meiosis
between the two genes (Conneally and Rivas 1980). Linkage is the
tendency of genes on the same chromosomes to segregate together, i.e.,
linked gents are transmitted to the same gamete more than 50% of the
time. The closer genes art to each other, the more frequently they
will be transmitted together. On the other hand, genes that are far
apart on same of the larger chromosomes may segregate randomly in
relation to each other, even though they are on the same chromosome.
All genes that are located on the same chromosome art said to be
syntenic. While all genes that are linked are syntenic, the converse
may not be true. Linkage analysis requires the study of families.
Generally, families in which a genetic trait of interest occurs are
examined, Until recently, most linkage studies have used the pheno-
typic polymorphic traits of the red blood cell antigens, red blood
cell isoenzymes, serum proteins, and HLA variants. Through the use
of statistical analysis, lod scores can be obtained and these reflect
the likelihood that two genes are linked to each other and how close
they may be. Because of the relative limited number of polymorphic
phenotypic markers available and because these cover only a fraction
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of the total human genome (about 20%), genetic linkage analysis
has not been highly successful. However, with the introduction of
the DNA RFLPs, a new era has arrived in human gene mapping and, in
theory, it is now possible to map any human gene through this
approach.
All genetic variation reflects differences at the DNA level. This
is true for the phenotypic markers which reflect genetic changes
based upon differences between alleles that can be determined by
electrophoretic techniques, immunological techniques, or other
biochemical methods. With the RFLPs of DNA, one detects these
differences directly in the DNA. Study of these polymorphisms is
based upon the following. Restriction endonucleases split DNA at
specific base sequences. These base sequences at the same site in
the DNA may vary between persons. With the use of different
restriction endonucleases, potentially a large number of different
base sequences may be detected in a population of individuals. By
isolating DNA from cells of individuals and treating the DNA with
restriction endonucleases, one can separate the DNA fragments by
molecular size using agarose gel electrophoresis. One then hybrid-
izes radioactively labeled DNA probes of specific function or DNA
probes of nonspecific or unidentified functions (anonymous probes)
to the DNA which has been treated with the restriction endonucleases
and separated by the electrophoresis. Differences in the size of
the DNA segments can be detected with the probes. These differences
can then be treated by the standard linkage approach described above.
The DNA RFLPs have a number of advantages (table 1). With the
availability of a large number of restriction endonucleases, it is
very likely that each and every gene will be found to demonstrate
polymorphisms following treatment with one or more of these restric-
tion endonucleases. It has been estimated that perhaps only 165 DNA
probes could span or map the human genome (Botstein et al. 1980).
This would be true if the probes were mapped at random. However,
it has been estimated that many more markers may have to be studied
and evaluated in order to find the minimum number which would be
randomly distributed over the genome (Lange and Boehnke 1982).
Nevertheless, it appears at this time that with sufficient effort
the appropriate probes can be isolated and used to eventually map
the whole human genome. It should be noted that these DNA
probes can also be used in conjunction with the somatic cell hybrid-
ization approach referred to above. In addition, they can be used
in a new approach called in situ hybridization in which the radio-
active probe is hybridized directly to chromosomes on a microscope
slide.
Many human genes are being rapidly mapped through the use of the DNA
probes using these three methods: linkage, somatic cell hybridiza-
tion, and in situ hybridization. For example, one prominent example
using this recombinant DNA approach has been the demonstration of
linkage of the gene for Huntington's disease to an anonymous gene
identified by the DNA probe, G8 (Gusella et al. 1983). Although
still not applicable at the clinical level, these developments offer
the prospect in the near future of being able to enhance genetic
counseling for families in which Huntington's disease occurs. Poten-
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tially, such an approach could be used to make prenatal diagnosis to
identify persons at risk not only before the symptoms start, but
even before the individual is born.
1.
2.
3.
Gene or DNA sequence need not be expressed;
RFLPs can be found in all regions of the genome;
Probably all genes or DNA sequences can be "made"
polymorphic with use of different restriction
endonucleases;
4. Same technique is used for all markers;
5. May lead to isolation of a gene of interest; and
6. Any gene should be "linkable."
TABLE 1
Advantages of DNA RFLPs
ASSOCIATION
Genetic linkage and association are terms that are often used inter-
changeably, but they describe different phenomena with different
implications (Vogel and Motulsky 1979; Hedge and Spence 1981). How-
ever, within a single family it may not be possible to distinguish
linkage from association. Evaluation of each requires the use of
genetic polymorphisms, which may in part contribute to the confusion.
Linkage relates to genetic loci, and the alleles at these loci are
useful only as markers for the loci. Evaluation of linkage requires
the study of families, especially large families. Association refers
to a concurrence greater than predicted by chance between a specific
allele at a locus and another, trait which may or may not have an
obvious genetic basis. Evaluation of association requires the study
of unrelated individuals. Association may give an insight into sus-
ceptibility and pathogenesis of a trait or disease. Thus, association
studies may be used to identify a genetic factor in a disease. With
the exception of linkage disequilibrium, association is not due to
linkage. Association may result from: pleiotrophic effects of a
single gene; epistatic interaction; selection in relation to environ-
mental factors (for example, sickle cell gene and malarial resistance);
and population stratification.
The early examples of association are related to the ABO blood groups,
because this was the earliest polymorphic trait available for study.
Examples of significant associations between the ABO blood groups and
diseases include a higher frequency of blood type A in persons with
neoplasia of the intestinal tract, cervix, and breast, while there
is increased frequency of blood type O in persons with duodenal and
gastric ulcers. However, these associations are not sufficiently
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strong to have clinical importance. When the highly polymorphic HLA
system became available, it was applied to a large number of diseases
in a search for associations. Some of the significant associations
between HLA and diseases include type B27 with ankylosing spondy-
litis and Reiter's disease, and type DR3/4 with insulin-dependent
diabetes mellitus.
In addition to the association of the sickle cell gene and the
resistance to malaria noted above, a similar resistance has been
noted for G6PD deficiency and malaria. Another association that
has been described in relation to malaria is the Duffy blood group
system in which individuals of the Fy(a-b-) phenotype demonstrate
resistance to malaria. Evidence has been presented that the Duffy
a and b antigens may act as red cell receptors for malaria parasites.
As expected, the genomic types for the resistance to malaria have
been found to occur with a high frequency in malarial areas. These
are also nice examples of how environmental factors may contribute
to specific allelic frequencies.
Demonstration of associations may help to: identify a genetic com-
ponent to a disease; clarify pathogenesis of a disease; facilitate
preclinical testing to identify persons at risk so that appropriate
counsel may be given; and recognize disease heterogeneity.
Thus, associations may be important in determining whether a specific
genetic variant is associated with reaction to a drug or alcoholism.
On the other hand, genetic linkage may be useful to identify a gene
or genes which may be important in determining reactions to a drug or
alcohol, but whose function is not known. From linkage to a testable
polymorphic gene marker, one may be able to identify who in a family
may be at risk to have a gene for drug abuse or alcoholism.
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Individual Differences in Opiate-Induced
Alterations at the Cytogenetic, DNA Repair,
and Immunologic Levels: Opportunity for
Genetic Assessment
Arthur Falek, Ph.D.; John J. Madden, Ph.D.; David A. Shafer,
Ph.D.; and Robert M. Donahoe, Ph.D.
In humans there are several strategies to identify the signif-
icance of hereditary factors underlying the occurrence of a
behavioral and/or physical trait, including: a) family studies,
b) twin studies, c) linkage studies to a genetic marker, and d)
adoption studies. In particular, where expression of a trait
may be influenced by sociocultural factors, consistent findings
are required from several strategies to support the importance
of genetic factors. For example, family, twin, genetic marker
and adoption studies (Goodwin 1981) have provided consistent
support for the importance of a genetic component for
alcoholism.
Linkage studies of specific traits with genetic markers have
recently been expanded from linkage by blood groups, HLA
haplotypes, and other such chromosomally located protein markers
to those linked by specific DNA probes such as the recently
announced linkage between a polymorphic DNA probe on the short
arm of chromosome 4 and Huntington’s disease (Gusella et al.
1983; Vesell 1984). This new approach is limited at present to
the study of clearly identified single gene inherited disorders
but may in the future be appropriate for studies of apparent
polygenetic traits with strong environmental components such as
alcoholism.
While genetic studies employing different strategies have
demonstrated the importance of the genetic component in
alcoholism. unfortunately no such self-consistent data have been
obtained for opiate abuse. As reported by Liston and associates
(Liston et al. 1981) and reaffirmed most recently in our search
of the drug abuse literature, there is a paucity of information
on the contribution made by genetic factors to individual
differences in response to opiates among humans. On the other
hand, as noted by Liston and associates, there have been studies
of genetic influences on performance after opiate use as well as
on preference in animals for morphine. These studies demon-
strated that there were significant differences in locomotor
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activity among different strains of rats following morphine
administration (Eidelberg et al. 1975). They also found that
rats could be bred with a preference for morphine (Nichols and
Hsiao 1967) and that mice inbred for alcohol use also preferred
morphine (Eriksson and Kiianmaa 1971). These animal studies
demonstrating genetic mechanisms underlying variability in
response to morphine are reviewed by Dr. Shuster (this volume).
In humans, the physiological (cold pressor test) and
psychological parameters of responses to pain and to morphine in
10 sets of normal monozygotic male twins were measured (Liston
et al. 1981). This study (from the VA Hospital in Los Angeles)
provided no evidence for a genetic component in response to pain
(either pain threshold or pain tolerance) before or after
administration of morphine. Although these investigators did
find significant twin pair effects on two measures of anxiety,
they indicated that the number of twin sets in their study was
too small to produce significant differences between pairs as
compared with differences between the twin partners. The only
other report in the literature on genetic aspects of opiates in
humans is on one pair of monozygotic twins discordant for heroin
abuse (Grumet 1983).
Our own study of cellular genetic aspects of opiate abuse was
initiated to determine whether there was an impact on the genome
among humans using opiates. Initial studies were conducted to
examine levels of chromosome damage (CD) among opiate addicts as
compared with controls, since an increased level of such
chromosome alterations implies DNA damage and often may be
correlated with an increase in mutational events. For the first
study, we compared leukocyte chromosomes of 16 addicts with 16
controls (Falek et al. 1972). Our findings revealed 32 random
chromosome aberrations among the 16 drug patients for a rate of
2.7% (calculated in the first study as the number of aberrations
found divided by the number of metaphase chromosome complements
scanned) as compared with 4 chromosome breaks in the leukocytes
of the 16 control subjects for a rate of 0.4%. We consistently
found a frequency of 0.4% chromosome damage among normal
populations during the time we were conducting these studies.
There were some opiate addicts who showed no evidence of
chromosome damage and obviously there were others who displayed
more than 2 damaged chromosomes to provide the 32 damaged
chromosomes among the almost 1,200 metaphase complements
analyzed. There was no correlation of the chromosome damage
level in the addicts with the length of time of drug use, the
type of street opiate, or the abuse of other drugs. Further
studies in which addicts were followed longitudinally for a
period of more than 1 year through methadone treatment or
nonchemical detoxification provided evidence that the increased
number of damaged chromosomes at time of admission also
reflected a significantly increased frequency of cells with at
least one damaged chromosome (Falek and McFadden 1973; Falek and
Hollingsworth 1980). Inter- and intra-individual variability
was clearly evident from one time point to the next (table 1).
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After a year the CD levels were reduced to about 0.6% for those
remaining in the study, which was not significantly different
from the 0.4% found for normal controls. Evidence that the
increase in CD was opiate induced rather than a result of other
environmental factors was provided in cytogenetic studies in
which street opiates or morphine were given to rhesus monkeys
(Fischman et al. 1983). As with the human addicts, there was a
significant increase in CD in the opiate treated monkeys as
compared with controls, proving that the CD increase was not
merely ascribable to the human addict milieu.
TABLE 1
INDIVIDUAL VARIABILITY IN DRUG ADDICTS FOLLOWED FOR
8 WEEKS IN METHADONE TREATMENT
Cells with Chromosome Breakage
Cases
1
Pre-
Methadone
1
24 hours 8 weeks
Post- Methadone
Methadone Maintenance
1 5
2
3
4
5
6
7
8
9
10
4 1
1 0
1 1
1 6
5 0
0 1
0 6
2 6
3 6
1
1
1
2
0
3
2
5
2
A second method of examining the question of chromosome damage
is by the study of sister chromatid exchange frequencies (SCE).
SCE and CD are known to be the products of independent
mechanisms that result from different types or conditions of DNA
damage (Galloway and Wolff 1979; Lin and Wertelecki 1982). SCE
occurs with a much higher frequency than CD, and such analysis
has become established as a rapid, sensitive, and quantitative
assay to determine genetic damage (Shafer 1982). It is evident
from the literature that: 1) there are individual differences in
baseline frequency among people (Crossen 1982); 2) there is a
hereditary component in SCE formation indicated by significant
sib-sib and parent-child, but not parent-parent, correlations in
SCE base levels (Cohen et al. 1982); 3) there are increased SCE
base levels or specific SCE sensitivities in such genetic
diseases as Bloom's syndrome, xeroderma pigmentosum, or
Fanconi's anemia (Ray and German 1982); 4) there are
significantly elevated rates of SCE after in Vivo exposure to
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known mutagens (Hansteen 1982); and 5) increased SCE induction
in vivo is significantly correlated with later carcinogenesis or
transformation (Popescu and Dipaolo 1982; Raposa 1984). As to
when such effects may occur in the cell cycle, SCE can only be
induced by treatments prior to completion of S phase
replication, while CD can also be induced by G2 treatments
with mutagens such as X-ray and radiomimetic agents.
Figure 1 is a histogram of SCE base levels for 47 heroin addicts
and 39 controls (Shafer et al. 1983). There were differences in
base level counts among individuals scored as SCEs/cell in the
chromosomes of about 15 metaphase cells per individual. In the
opiate addict population, the mean ranged from approximately 8.5
to 20.5 with an overall mean of 13.82 ± 4.76 SCE/cell. For
controls, individual mean SCE scores ranged from 5.5 to 15.2
with an overall mean score for controls of 11.16 ± 3.97.
Analysis of variance indicates a highly significant difference
between the opiate and control groups (F = 22.00, p 0.001).
Individual differences were observed in the frequency of SCE not
only when opiate addicts were compared with controls at base
levels, but also when the lymphocytes from both populations were
exposed to far ultraviolet light (far UV) at G1 and S in the
cell cycle. Figure 2 shows a histogram of SCE counts at base
level as well as after exposure to far UV (14J/m2 with
Morowitz correction) at G1 (18 hours before harvest) and at S
(12 hours before harvest). When base level and UV induced SCE
frequencies are compared for individual subjects, the data
demonstrate that interindividual variability plays a significant
role in SCE responses to far UV stress. Analysis of variance
with repeated measures (to simultaneously and separately
compared SCE means at base level and at the two treatment points
for each individual) as well as use of the nonparametric
Mann-Whitney U test confirmed that the SCE frequencies among
heroin addicts were significantly higher than controls and that
the increase at base level was paralleled by increases of
comparable magnitude with UV treatments at these time points.
Our studies on DNA repair synthesis (DRS) induced by far UV
likewise demonstrate individual response differences (Madden
et al. 1979). DES is defined as a mutagen induced increase in
the incorporation. of thymidine into all precipitable cellular
DNA beyond that incorporated by semiconservative replication.
DRS is presumptively an indicator of DNA excision repair and as
such has been used to identify such genetic defects as xeroderma
pigmentosum (Cleaver and Bootsma 1975). We, therefore,
investigated repair of far UV damage to determine whether there
was etiologic evidence to explain the observed increase in
chromosome damage among opiate addicts and the decrease in such
damage in many long-term methadone patients.
DNA repair synthesis fluence curves for different subjects
generally show a linear increase in thymidine incorporation with
increases in far UV doses up to 15 to 20 J/m2, but a few
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FIGURE 1
Distribution histogram of SCE base levels in heroin and
control subjects based on all subjects analyzed. The
difference between the means was highly significant and the
variances within each group were statistically similar.
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FIGURE 2
Distribution histogram of SCE levels for those heroin and
control subjects with data for all three treatment points:
base level, and UV at 12 and 18 hr. While significant
differences were most pronounced at the base level and at the
Gl UV treatment, even the slight difference in the means of
the early 5 UV treatment is supported by the data
distribution.
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individuals reach maximal incorporation at <5 J/m2 (poor
repairers), while others are saturated only at doses of >50
J/m2 (super repairers). The repair capacity is defined as the
plateau level of the curve (i.e., the maximum measurable
thymidine incorporated). The control subjects demonstrated a
marked individual response to far UV, with a mean value of
14,700 dpm/A260 and a standard deviation of ±9,700 dpm/Al60.
This result supported the hypothesis of significant variability
in the capacity of leukocytes of individuals in the general
population to handle fluences of far UV. Variables such as age,
sex, or alcohol use did not significantly contribute to the
variance, but tobacco use significantly lowered the mean DRS
score to 10,300 dpm/A260, primarily as a result of the loss of
high repairers from the group. In contrast, heroin addiction
produced an even greater decrease in the mean of far UV induced
repair in comparison to controls as evidenced by a shift in the
maximal DRS response to largely the poor and low median portion
of the curve (X = 4,300 dpm/A260 ± 4,200). After long-term
methadone treatment (X = 4.8 years), there was no significant
difference between patients in treatment and controls
(X = 13,200 dpm/A260 ± 9,300). These data imply a correlation
between DNA repair and chromosome damage levels. When DNA
repair level is depressed, there is an increased frequency in
cytogenetic effects, while the cytogenetic damage is depressed
when DNA repair returns to more normal levels.
Based on the cytogenetic and DNA repair findings, we conducted
immunologic explorations to more specifically define the
leukocyte cell type or types involved in these repair and
cytogenetic changes (McDonough et al. 1980, 1981; Donahoe et al.
1985a). While there were no significant changes observed in B
lymphocytes or total white blood cell count, the T cell values
decreased significantly from approximately 69% found in the
control population to about 33% in the addict population (figure
3). The addicts in the study were on street heroin almost
exclusively for approximately 10 years. For the long-term
methadone patients, the E rosette frequency was increased to
56.7%. It is clear in both the addict and methadone populations
that there is a great diversity in individual response. When
viewed over time, as seen in figure 4, the data show that on the
average the E rosette depression becomes more severe the longer
the addict uses street opiates, but, as seen in the outliers,
this does not totally account for the variability in rosetting.
Similarly, individual differences are displayed in figure 5
regarding the effect of methadone therapy on the percent of
circulating E-rosette forming lymphocytes. This somewhat
unpredictable response to opiates and therapy was also reported
by Brown and colleagues (1974) in their study of mitogen induced
growth of lymphocytes from patients followed longitudinally
during methadone therapy.
Kinetic assay studies to assess opiate effects on rates of T
cell E-rosetting indicate that a major biological effect of the
opiates relates to their ability to modulate expression of
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FIGURE 3
Histogram of the percent sheep erythrocyte (E) rosettes
formed by lymphocytes from control subjects, heroin addicts,
and methadone clients.
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FIGURE 4
The effect of years of street heroin use on the percent
E rosettes formed by lymphocytes from addicts. The line shown
represents the best regression line which can be fitted to
the data.
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FIGURE 5
The effect of years of methadone use on percent E rosettes
formed by lymphocytes from methodone clients. The great
variability seen can arise both from variability in the
previous street drug history of the client (type of opiate,
average daily dose, length of time addicted, individual
response to street heroin) and from the individual response of
the client to the methadone. While there is a general return
to control percents of E rosettes, a few subjects show
pronounced rosette depressions even after years in therapy.
Because of the rigorous screening of these clients for illicit
drug use during this period, these outliers cannot be ascribed
to illicit drug use.
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regulatory proteins on the T cell membrane (Madden et al.
1983). We also found that opiate addiction associates with
altered expression of T cell antigenic markers which may occur
through opiate modulated enhancement of suppressor T cells,
resulting in a depression of Th/Ts ratio in long-term addicts
(Donahoe et al. 1985b). The observations that opiates have the
ability to modulate surface proteins/receptors on T cells
support the possibility that T cell constituencies among heroin
addicts are one of the bases for individual variation in the
expression of cytogenetic and DNA damage seen in our addict
populations. With the ability to secure relatively pure T cell
populations, it is now possible to investigate the genetic
aspects of such potential differences.
Our cytogenetic, biochemical, and immunologio assays provide
evidence of significant alterations in users of street opiates
as compared to controls, as well as individual differences in
response to street opiates and individual levels of amelioration
of these alterations over time with methadone. As indicated in
the introduction to this chapter, one method of genetic analysis
in humans, particularly with assays that apparently are not
directly under sociocultural influences, is based on concordance
rates in monozygotic (MZ) and dizygotic (DZ) twin partners.
Monozygotic twins are genetically alike while dizygotic twins
are no more similar than pairs of siblings in a family. In his
presidential address delivered before the Society for
Psychophysiological Research, David Lykken (1982) related that
human geneticists have concentrated on two basic mechanisms of
genetic transmission. He noted that mendelian mechanisms depend
on the presence or absence of a particular allele at a specific
gene locus, while the galtonian mechanisms are concerned with
polygenic transmission in which the value of a metrical trait
such as height is apparently determined by the additive action
of a number of genes at different loci. Dominance (between
alleles at one locus), simple epistasis (a type of dominance
between two genes at different loci), and polygene epistasis (a
nonadditive configuration resulting from interactions among more
than two independent or partly independent genes) may modify
polygenic transmission. In particular, the latter, while
genetic, may not run in a simple manner in families. To
determine whether or not such complications occur in responses
to and predilection for opiate use in humans, comparative twin
differences with regard to protein modulation or receptor number
on the T cell membrane between concordant and discordant MZ and
DZ twins may be a most fruitful approach to an examination of
the genetic aspects of this disorder.
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Pharmacogenetic Approaches to
the Prediction of Drug Response
Elliot S. Vesell, M.D.
As the chapters in this monograph illustrate, numerous genetic and
environmental factors can influence the metabolism and effects of
ethanol. Despite this recent progress in identifying these factors,
the underlying cause or pathogenesis of alcoholism and of abuse of
other substances remains illusive and ill defined.
It follows that the primary products of putative "causative" genes
are unknown. The genetic and environmental factors thus far
Investigated appear to be peripheral rather than primary with
respect to causation of the underlying behavioral aberration
associated with drug abuse. So imprecise are our present concepts of
specific genetic causes of drug abuse that recommendations for
research in this area are hazardous and difficult to justify if
strict criteria are applied.
PHARMACOGENETICS
Pharmacogenetics is defined as the study of specific genetic factors
that cause large interindividual variations in response to some
drugs. Pharmacogenetic investigations would not be likely to reveal
the pathogenesis of substance abuse, but rather might explain why
certain subjects who abuse alcohol and other drugs may be
particularly susceptible to injury and toxicity, whereas others who
take larger doses resist damage and do not develop the disease (Kalow
1962; Motulsky 1964; LaDu 1972; Vesell 1973; Kalow 1982; Propping
1978). For example, racial differences in an isozyme of aldehyde
hydrogenase explain the greater susceptibility of Oriental subjects
to such effects of ethanol as facial flushing; this example
illustrates the capability of pharmacogenetics to elucidate the
basis of interindividual variations in susceptibility to drug
toxicity and was discovered by a distinguished investigator in
pharmacogenetics, H. Werner Goedde (Goedde et al. 1979, 1984; Harada
et al. 1980; Agarwal et al. 1981). Another more controversial
example of pharmacogenetic progress in this area is the possible
association of the immunogenetic markers HLA-B40 and DRW9 with
alcoholic cirrhosis of the liver in Japanese subjects (Miyamoto et
al. 1983). Although certain HLA haplotypes are highly associated
with several disorders of a fundamentally immunologic nature, such
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as ankylosing spondylitis, lupus erythematosus, and rheumatoid
arthritis, several previous studies failed to observe such
associations of HLA haplotypes with alcoholic cirrhosis, a disease
not generally considered to be due to an immunologic abnormality.
However) recently, several immunologic abnormalities have been
described in patients with alcoholic cirrhosis (Sorrel1 and Leevy
1972; Tannenbaum et al. 1969; Tsuchimoto 1982).
In the area of abuse of drugs other than alcohol, no specific pharma-
cogenetic entities have thus far been identified. However, several
observations suggest that pharmacogenetic mechanisms might be
operative and might contribute to large lnterindividual variations
already documented to occur in the metabolism of methadone (Kreek
1973) and possibly in the metabolism of cocaine and heroin, two other
commonly abused drugs whose elimination from the body also occurs
mainly through biotransformation (Goodman and Gilman 1980).
In human subjects, pharmacokinetic values are more conveniently and
reliably measured than pharmacodynamic ones. Pharmacodynamic
variations undoubtedly also exist, and some of these may be
maintained by genetic mechanisms. However, it is not yet feasible to
obtain precise pharmacodynamic measurements noninvasively in human
subjects. Much technical progress is necessary before pharmaco-
dynamic measurements can be gathered in humans reliably, safely, and
noninvasively.
The following review of pharmacogenetic progress and methodology is
offered to stimulate and suggest analogous studies on drugs of
abuse. It is readily acknowledged that formidible methodological
problems are posed by adapting to drugs of abuse these
pharmacogenetic approaches based on the administration of single
safe doses of various prescription drugs to normal subjects under
carefully controlled environmental conditions. Results of similarly
designed studies on drugs of abuse in addicts might be
uninterpretable because of confounding by numerous environmental
perturbations, including the smoking of cigarettes and/or marijuana,
nutritional variations, and intake of other drugs such as ethanol.
Ethical considerations render objectionable the administration to
unaddicted subjects of drugs at dosage levels usually ingested by
drug abusers, Other approaches would have to be taken in such normal
subjects. Possibilities include administration of tracer doses of
14C- or 13C-labeled drugs or growth of normal cells in culture to
investigate their pharmacokinetic and/or pharmacodynamic responses
to various drugs of abuse.
DYNAMIC INTERACTIONS AMONG THE GENETIC AND ENVIRONMENTAL FACTORS
THAT MODIFY DRUG RESPONSE
Unlike the numerous problems that beset studies to identify factors
that cause pharmacokinetic variations among subjects after
administration of drugs of abuse, much progress has been achieved in
investigating such factors that influence the disposition of
prescribed drugs eliminated primarily through hepatic metabolism.
This progress has occurred largely through availability of normal
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human subjects who can safely ingest single doses of various model
drugs, such as antipyrine, aminopyrine, amobarbital, debrisoquine,
sparteine, mephenytoin, acetaminophen, theophylline, etc.
Antipyrine has proven particularly fruitful in disclosing numerous
environmental factors that can interact with each other as well as
with genetic factors to determine antipyrine elimination rates and
plasma antipyrine concentrations. The design of figure 1 suggests
dynamic interaction of such factors. In contrast to addicts, the
normal subjects used to identify the factors shown in figure 1 were
all carefully defined and uniform with respect to almost every
factor in the outer circle. This standardization of prevailing
environmental conditions among the subjects permitted each variable
to be investigated independently of all others. Dose-response
curves could be generated, relating increments of a specific factor
to subsequent changes in antipyrine disposition. This model drug
approach is exceedingly sensitive in detecting factors that can
affect drug disposition, mainly because each subject serves as his
or her own control (Vesell 1979). Use of subjects as their own
control eliminates extraneous contributions from many genetic and
environmental perturbations that occur in the alternative experi-
mental design where the control and experimental subjects differ,
forming two separate groups that are compared. Nevertheless, like
all laboratory tests, the model drug approach has limitations.
Occasionally, it has disappointed some investigators whose
expectations from it were unrealistic or unwarranted (Vesell 1979).
The main limitation as well as advantage of the model drug approach
depends directly on the pharmacologic characteristics of the drug
selected for administration. With respect to antipyrine, the
principal advantage is that antipyrine decay in saliva and plasma
reflects directly antipyrine metabolism in the liver by three
separate cytochrome P-450 mediated monooxygenases. Since antipyrine
is absorbed completely from the gastrointestinal tract, distributes
in “total body water,” is not bound significantly to tissue or plasma
proteins, and is not eliminated to an appreciable extent by renal
mechanisms, antipyrine decay in plasma and in saliva sensitively
reflects its rate of hepatic biotransformation. Furthermore, since
antipyrine is a drug with low hepatic extraction, its elimination is
independent of hepatic blood flow. No other model drug yet proposed
enjoys so many advantages as an indicator of hepatic drug-
metabolizing capacity. Nevertheless, antipyrine elimination can
only reflect the activities of a few of the many hepatic drug-
metabolizing enzymes. Other such enzymes not directly involved in
antipyrlne biotransformation may be influenced to a greater or
lesser extent than the antipyrine-metabolizing enzymes by a
particular genetic or environmental factor. Hence, these effects
may not be accurately disclosed with antipyrine. For example, the
metabolism of debrisoqulne and sparteine occurs through a different
cytochrome P-450 mediated monooxygenase. For this reason, if many
hepatic drug-metabolizing enzymes are to be investigated
simultaneously, several model drugs in addition to antipyrine need
to be used.
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FIGURE 1
This circular design suggests the multiplicity of either well-
established or suspected host factors that may influence drug
response in man. A line joins all such factors in the outer circle
to indicate their close interrelationship. Arrows from each factor
in the outer circle are wavy to indicate that effects of each host
factor on drug response may occur at multiple sites and through
different processes that include drug absorption, distribution,
metabolism, excretion, receptor action, and combinations thereof.
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PHARMACOGENETICS: GENE-DRUG INTERACTIONS THAT PRODUCE DISEASE
Pharmacogenetics, the study of genetically determined variations in
drug response, focuses on interindividual variations because they
are frequently encountered and often present clinical problems. For
example, the extent of these intersubject variations in response can
range from threefold to fortyfold, depending on the particular drug
and population. For drugs with low therapeutic indices, each
patient’s dosage regimen needs to be carefully adjusted to avoid
drug toxicity or undertreatment.
Since many drugs are plant alkaloids, it is not surprising that
genetic variations also exist in response to some dietary
constituents and that some inborn errors of metabolism are worsened
by dietary constituents. For example, galactosemia, phenyl-
ketonuria, Wilson’s disease, celiac disease, and lactose intolerance
due to lactase deficiency are exacerbated by foods containing
galactose, phenylalanine, copper, gluten, and milk, respectively.
Also, in several other inborn errors of intermediary metabolism,
crises can be precipitated by certain drugs. For example, in
diabetes mellitus, gout, and several forms of porphyria,
administration of adrenal glucocorticolds, thiazide diuretics, and
barbiturates, respectively, should be avoided.
Another group of inborn errors of metabolism exists in which the
aberrant (mutant) protein participates directly, rather than
indirectly, in drug disposition or action. These entitles, the main
focus in the past of the field of pharmacogenetics, include several
rare monogenically transmitted conditions (acatalasla, atypical
plasma cholinesterase, phenytoin sensitivity, and warfarin
resistance) as well as some commonly occurring monogenically
transmitted conditions (slow acetylation of isoniazid and other
drugs and glucose-6-phosphate dehydrogenase deficiency). Abundantly
reviewed in the past (Kalow 1962; Motulsky 1964; Vesell 1973; Vasell
and Penno 1983; LaDu 1972; Weinshilboum and Vesell 1984), these
pharmacogenetic conditions will not be described in detail here.
Each exemplifies how genetic constitution can determine drug
toxicity. In general, toxicity arises in a genetically susceptible
individual from accumulation of parent drug due to a block in its
biotransformation to inactive metabolites. Transmitted in classical
mendelian fashion by alleles at a single but different locus, each of
these metabolic blocks is described as monogenic. In most cases, a
double dose of a mutant gene is required to produce the defect
(recessive phenotype), but rarely, as in phenytoin toxicity, does a
single gene seem to suffice (dominant phenotype).
In 1968, the influence of genetic factors on drug response and
toxicity was extended well beyond the aforementioned monogenic
conditions to other entities encompassing different drugs (Penno et
al. 1981; Vesell and Page 1968a, 1968b, 1968c). These new
pharmacogenetic conditions involved drugs characterized by: (1)
extensive hepatic metabolism through cytochrome-P-450-dependent
monooxygenases and (ii) large interindividual variations in rates of
elimination. Almost a dozen different drugs were given to normal
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uninduced twins who were nonsmokers, otherwise unmedicated, and not
chronic consumers of ethanol. These drugs included antipyrine
(Penno et al. 1981; Vesell and Page 1968a), phenylbutazone (Vesell
and Page 1968b), bishydroxycoumarin (Vesell and Page 1968c),
ethanol (Vasell et al. 1971). halothane (Cascorbi et al. 1971).
nortriptyline (Alexanderson et. al. 1969), amobarbital (Endrenyi et
al. 1976), phenytoin (Andreasen et al. 1973), salicylate (Furst et
al. 1977), and tolbutamide (Scott and Poffenbarger 1979).
Genetic control over extensive interindividual variations in rates
of elimination of these drugs was indicated by larger
pharmacokinetic differences within dizygotic than within monozygotic
twins (Penno et al. 1981; Vesell and Page 1968a, 1968b, 1968c; Vesell
et al. 1971; Cascorbi et al. 1971; Alexanderson et al. 1969; Endrenyi
et al. 1976; Andreasen et al. 1973; Furst et al. 1977. Scott and
Poffenbarger 1979). Intraindividual variations were small compared
to interindividual variations in these carefully selected, uninduced
twins living under uniform environmental conditions. Although such
observations supported a genetic basis for the large interindividual
variations in the disposition of these drugs, the precise mendelian
mode of transmission of these factors could not be elucidated just
from the twin studies on parent drugs. Thus, when pedigree analysis
was attempted solely on the basis of kinetic studies performed on the
parent drug, rather than on principal metabolites, the mode of
transmission of interindividual variations for bishydroxycoumarin
(Motulsky 1964), phenylbutazone (Whittaker and Price Evans 1970),
and nortriptyline (Asberg et al. 1971) was either unclear or else
more compatible with a polygenlc than a monogenic mechanism. In
light of the current information discussed below, a polygenic
attribution is misleading because more recent examinations of
individual metabolic pathways have disclosed monogenic transmission.
Since some twins participated in several of these studies, it was
possible to determine whether their rates of biotransformation of
different drugs were closely correlated. Although some correlations
occurred, rates of clearance of most drugs investigated were
independent of one another (Vesell and Page 1968c). This result was
notable for several reasons. It suggested that the twin studies had
disclosed several discrete genetic entities, rather than one or two
that determined large variations in the metabolism of numerous
drugs. Furthermore, the existence of separate genetic entities,
each involving a different molecular form (isozyme) of hepatic
cytochrome P-450, agreed with simultaneously emerging evidence for
extensive heterogeneity of this hepatic hemoprotein (Alvares et al.
1969; Lu and Levin 1974; Nebert et al. 1982; Ryan et al. 1975; Wang
et al. 1980).
THE DEBRISOQUINE POLYMORPHISM
In 1977, a landmark report disclosed that approximately 7% to 9% of
the population in the United Kingdom were genetically slow
metabolizers of the antihypertensive drug debrisoquine (Mahgoub et
al. 1977). After a 10-mg oral dose of debrisoquine, the phenotypes
of extensive metabolizers (EMS) and poor metabolizers (PMs) were
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distinguished in an 8-hour urine specimen by the ratio between the
percent of the dose eliminated as the parent drug and the percent
removed as its principal metabolite, 4-hydroxydebrisoquine. A ratio
of 10 or more characterized deficient (poor) metabolizers of
debrisoquine. This phenotype was conferred by a double dose of an
autosomal gene. In patients treated with debrisoquine, toxicity
occurred predominantly among deficient metabolizers. Thus, two
alleles at a single genetic locus largely determine susceptibility
to adverse effects from this drug.
Using sparteine rather than debrisoquine, Eichelbaum’s group in Bonn
reported a monogenically controlled variation which now appears to
be identical in many respects to the debrisoquine polymorphism
(Eichelbaum et al. 1979). In German subjects, the frequency of this
inability to metabolize sparteine approximated that for debrisoquine
in the United Kingdom. This meant that in the United Kingdom and
Germany, for every 100,000 patients receiving usual doses of
debrisoquine or sparteine, approximately 7,000 to 9,000 would be at
risk of toxicity due to drug accumulation.
The group from the United Kingdom extended the soope of their
discovery by suggesting a panel drug approach (Idle et al. 1979):
slow metabolizers of debrisoquine were shown to be incapable of
blotransforming several other drugs as well. Thus, deficient (poor)
metabolism of debrisoquine was demonstrated to be associated with
poor metabolism of nortriptyline (Bertilsson et al. 1980; Mellstrom
et al. 1981); phenacetin (Sloan et al. 1978); phenformin (Shah et al.
1980); certain ß-adrenoceptor blocking drugs such as metoprolol,
alprenolol, bufuralol, timolol (Alvan et al. 1982), and propranolol
(Shah et al. 1982a); guanoxan (Sloan et al. 1978); perhexiline (Shah
et al. 1982b); encainide (Wang et al. 1984); and possibly D-
penicillamine (Panayi et al. 1983). The genetic locus controlling
debrisoquine metabolism could be designated "a gene of multiple
effect." Since genetically deficient metabolizers of debrisoquine
are also at increased risk of toxicity from decreased
biotransformation of approximately 21 drugs, a clinically useful
predictive teat based on drug-oxidizing capacity seems to be
indicated. In such genetically predisposed subjects and certain of
their sibs, doses of these drugs could then be appropriately reduced
or alternative drugs selected that are metabolized by other pathways
of hepatic drug oxidation, thereby avoiding the dose-dependent
adverse reactions that occur moat frequently in the deficient
phenotype. The metabolic conversion and pharmacological actions of
numerous drugs are affected to varying extents and in differing ways
by the debrisoquine polymorphism. Thus, the precise clinical
consequences of the PM phenotype relate directly to the special
properties of the particular drug administered (Idle et al. 1983):
(i) For drugs like the ß-adrenergic blockers whose hepatic ex-
traction is high and whose elimination is therefore blood-
flow dependent, oral bioavailability would be enhanced
perhaps fourfold or fivefold in PMS compared to EMs. The
clinical consequences in the PM phenotype consist of
exaggerated pharmacological responses to such drugs.
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(ii) For drugs whose elimination requires metabolic oxidation,
drug accumulation in PM phenotypes could produce toxicity,
as in the neuropathy and liver damage after perhexilene
that occur primarily in the PM phenotype (Shah et al.
1982b).
(iii) For the few drugs that require conversion to a metabolite
before becoming pharmacologically active, such as encainide
Wang et al. 1984), where oxidative O-demethylatlon to
desmethyl-encainide is necessary for antiarrhythmic
effects, the PM phenotype will be resistant to therapeutic
effects and, hence, deprived of benefit from the drug.
(iv) For drugs such as phenacetin, the PM phenotype may, due to
blockage in one oxidative pathway, develop toxicity due to
enhanced production of a toxic metabolite via a minor
pathway. The PM phenotype is much more liable to toxicity
then the EM phenotype because in the PM phenotype, when O-
deethylation of phenacetin to acetaminophen is blocked,
much more phenacetin than normal is subject to the aromatic
oxidation and deacetylation to form hepatotoxic end
hemolytic p-phenetidins (Sloan et al. 1978).
This list of consequences could be extended, but these examples
suffice to illustrate the wide variety of clinical outcomes to be
anticipated from polymorphic oxidation and how these clinical
sequelae closely reflect the special metabolic profile and
pharmacologic characteristics of the particular drug administered.
Due to the considerable clinical consequences of polymorphic
oxidation of several drugs, Idle et al. (1983) suggested that when
administration of some of these commonly used drugs with low thera-
peutic indices is contemplated, patients should first be phenotyped
to permit efficient and safe tailoring of dose to their individual
metabolic requirements. To perform this service, regional centers
were advocated (Idle et al. 1983). Furthermore, in new drug develop-
ment where preclinical studies revealed metabolic oxidation as a
significant part of the total elimination process, this fact could
contraindicate further development of the drug or at least its use in
PM phenotypes (Idle et al. 1983). While this suggestion may seem
stringent, it could represent a theoretical possibility for a new
drug that produces very high toxicity or lethality in the PM
phenotype. Perhaps most such potentially dangerous new drugs never
reach clinical trial, obviating the need for phenotyping. Jack et
al. (1983) term "unwise" the suggestion that polymorphic or other
types of variable hepatic metabolism of a new drug contraindicate
its use or further development. They cite, to defend their position,
wide benefit from propranolol, isoniazid, phenytoin, and many
tricyclic antidepressants, none of which, they state, would have
been marketed under such restrictive policy. Finally, they consider it
unnecessary to establish regional centers to phenotype patients
before they receive polymorphically oxidized drugs. They believe
that most physicians can safely individualize dosage of such drugs
without prior phenotyping.
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In addition to its numerous clinical applications, the debrisoquine
polymorphism underscores several fundamental principles of pharmaco-
genetic investigation. For example, the debrisoquine polymorphism
could only have been discovered after development of sensitive high-
performance liquid chromatography techniques to detect and quantify
the principal metabolite, 4-hydroxydebrisoquine. In pharmacogenetic
studies, rates of formation of the main metabolites should be
measured, not just elimination rates of parent drugs, particularly
for drugs biotransformed by multiple pathways, because
identification of principal metabolites permits phenotyping of
subjects closer to their primary gene products (Kalow et al. 1977).
Another technical aspect of the debrisoquine story is facilitation
of genetic analysis by availability of a convenient, noninvasive
method, the metabolic ratio, to phenotype subjects. Use of the
metabolic ratio permitted rapid comparison of gene frequencies in
different populations.
These population data, interesting from several points of view,
demonstrate qualitative as well as quantitative variations in the
gene in different groups and countries (Kalow 1984). Not only do
allele frequencies change, but also genetic heterogeneity occurs;
that is, presence of additional alleles at this locus in subjects
from Ghana (Woolhouse et al. 1979, 1983). Comparisons of
debrisoquine phenotypes in five different populations (Canadian
Caucasian, Canadian Oriental, Saudi Arabian, Ghanian, and Nigerian)
suggested greater complexity than initially thought: all five
populations differed from one another in certain respects (see table
1 in Kalow 1984).
Genetic heterogeneity traditionally emerges after meticulous
investigation, in different countries or regions, of a locus that
appears initially, on the basis of limited population sampling, to
possess only two alleles. From the point of view of
pharmacogenetics, greater complexity of the debrisoquine
polymorphism than originally anticipated has several implications.
First, the nature of the alleles that occur commonly for this poly-
morphism should be characterized in a population and country before
new drugs affected by this polymorphism are widely given, at least on
only a single dosage schedule. Second, even though a screening
procedure to define phenotypes may be satisfactory in a particular
population, it may be unsatisfactory in another population where
different alleles predominate. Specifically, Kalow considers the
approach of phenotyping subjects according to their metabolic ratio
of debrisoquine to 4-hydroxydebrisoquine in a single 8-hour
collection of urine satisfactory in Caucasians but unreliable in
native Africans (Kalow 1984; Inaba et al. 1981). Careful kinetic
studies on the disposition of debrisoquine and its principal
metabolite have been performed in Caucasian PMs and EMs to teat the
validity of the metabolic ratio as a method to phenotype subjects
(Sloan et al. 1983).
Another contribution of the debrisoquine polymorphism has been
stimulation of the search for other genetically controlled
variations of drug oxidation. Extensive heterogeneity of the cyto-
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chrome P-450 system also favored the premise that additional poly-
morphisms of drug oxidation exist. The search has been rewarding.
New polymorphisms, distinct from debrisoquine, have been described
for mephenytoin (Kupfer et al. 1981) and antipyrine (Penno et al.
1981; Penno and Vesell 1983). The antipyrine polymorphism was
uncovered by application of a two-stage method that should enable
still other polymorphisms to be identified.
POLYMORPHIC METABOLISM OF ANTIPYRINE
Even before the discovery in 1983 of a polymorphism of antipyrine
oxidation independent of that for debrisoquine (Penno and Vesell
1983), its existence was suggested by circumstantial evidence. In
the first place, twin studies in 1968 and 1981 revealed genetic
control over large variations not only of antipyrine elimination
(Vesell and Page 1968a), but also of rates of formation "of the three
main antipyrine metabolites (Penno et al. 1981). Second, PM
phenotypes for debrisoquine and sparteine biotransformed antipyrine
normally, not at reduced rates (Bertilsson et al. 1980; Danhof et al.
1981). Third, studies on induction of antipyrine metabolism in rata
suggested that each of its three principal metabolites arose from a
different hepatic cytochrome P-450 isozyme (Danhof et al. 1979;
Inaba et al. 1980).
Analysis of 13 families provided evidence for a commonly occurring
polymorphism of antipyrine metabolism maintained by two codominant
alleles at one or more loci with frequencies of 0.8 to 0.9 and 0.2 to
0.1 (Penno and Vasell 1983). A common genetic mechanism regulating
all cytochrome P-450 isozymes responsible for the three main
antipyrine metabolites was suggested not only by the similar
frequencies for the alleles that control variations in rates of
formation of each antipyrlne metabolite, but also by the significant
correlation among these different rate constants within each subject
(Penno and Vesell 1983). These observations are also oonsistent
with a more complex interpretation that genetic control is
maintained by some regulatory factors that are identical for all
three loci and other such factors that differ at these loci.
Since the method developed to identify the antipyrine polymorphisms
(Penno and Vesell 1983) permits searches for other polymorphisms and
has just been used in our laboratory to define a new polymorphism of
theophylline metabolism, It merits some discussion. The first step
is to measure rate constants of formation of principal metabolites
of a drug or of their partial clearances in a sufficient number of
unrelated subjects (approximately 100) to generate distribution
curves. Without this essential first step, pedigree analysis
becomes uncertain due to the absence of an alternative way that is
both quantitative and objective to determine the phenotype of each
family member. Selection of 100 subjects follows from principles
governing population genetics. Enough unrelated subjects need to be
included in the sample so that a mode represents the rarer phenotype,
either in homozygous or heterozygous form, i.e., the phenotype
controlled by an allele q with a gene frequency of approximately 0.1
(p = 0.9; q = 0.21). If q were much less than 0.1, phenotypes
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corresponding to q (homozygotes) and 2 pq (heterozygotes) would be
undetectable since this method is not feasible for screening the
many hundreds of subjects that would be required. For example, if q
were 0.01, only 1 in 1,000 subjects would be homozygous at this locus
and only 2 in 100 would be heterozygotes. Some samples of 100
subjects might not contain even one heterozygote. Approximately 1
subject in 100 would be homozygous for an allele q if q = 0.1 (0.12:
but even in the absence of that single subject from several samples
of 100 subjects, the polymorphism would still be readily detected
because 18 of the 100 subjects investigated (2 pq or 2 x 0.9 x 0.1)
would theoretically be heterozygotes and phenotypically distin-
guishable on distribution curves and probits from the 81 subjects
homozygous (0.92) for the more frequently occurring allele p.
Once constructed on the basis of results in 100 unrelated subjects,
these distribution curves and probits serve to phenotype members of
different families, possibly drawn from index cases at the far ends
of the curve. Transmission patterns of these phenotypes which can be
objectively assigned to each family member are then traced to deter-
mine whether they conform to a mendelian mode of inheritance. If so,
this constitutes evidence for, but by no means unequivocally
establishes, a genetic polymorphism of drug oxidation. If patterns
of transmission in families are incompatible with mendelian laws, a
monogenic mechanism is rejected. However, before a monogenic
hypothesis is completely rejected, the family should be rechecked to
assure that the drug-metabolizing capacity of each member was truly
uninduced or uninhibited. For example, in the course of studies on
the antipyrine polymorphism, we encountered only one family that
contradicted a monogenic hypothesis (see figure 2 in Vesell 1984).
On questioning, the mother admitted taking cimetidine; on restudy,
after 3 weeks off cimetidine, she changed her values considerably,
thereby making the transmission pattern in the family consistent
with mendelian expectations.
When assessing the potential clinical significance of a genetic
polymorphism controlling cytochrome P-450 isozymes subject to exten-
sive environmental perturbations, one should recall several points.
First, virtually all cytochrome P-450 isozymes are subject to
environmental perturbation. Differences are mainly in the extent of
induction. Furthermore, polymorphisms that may at first appear
resistant may show, on further study, sensitivity to initially
untested drugs, chemicals, or conditions. Second, additional
alleles not encountered at a genetic locus on early study may appear
later when different populations are tested. These new alleles
might regulate cytochrome P-450 isozymes that are much different in
inductive responsiveness. For these reasons, certain genetic poly-
morphisms of drug metabolism may possess more clinical significance
and complexity than initially appeared, and the search for more such
polymorphisms should be encouraged.
THERAPEUTIC AND TOXIC DRUG RESPONSES CONTROLLED BY GENES AT HLA LOCI
For reasons as yet unclear, some uncommon alleles at the HLA loci may
be much more strongly associated with certain drug responses than
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alternative alleles. For example, in schizophrenic patients, HLA-A1
has been reported to be highly associated with a favorable response
to chlorpromazine (Smeraldi et al. 1976; Smeraldi and Scorza-
Smeraldi 1976). By contrast, HLA-A2 appeared to be associated with
an unfavorable response. In patients with affective disorders
treated with lithium, HLA-A3 was associated with a high rate of
relapse (Perris et al. 1979).
With respect to adverse reactions to drugs, in patients with
rheumatoid arthritis treated with sodium aurothiomalate, adverse
reactions (particularly proteinuria) occurred 32 times more
frequently in the HLA-DR3 haplotype (Wooley et al. 1980). Also, in
patients with rheumatoid arthritis, agranulocytosis after levamisole
was encountered much more frequently in subjects with the rare
haplotype HLA-B27 (Schmidt and Mueller-Eckhardt 1977). Hydralazine-
induced systemic lupus erythematosis occurred two to three times
more frequently in hypertensive patients with HLA-DR4 haplotype who
received the drug (Batchelor et al. 1980). Another genetically
determined phenotype, slow acetylation of hydralazine, also is
associated with increased susceptibility to lupus (Perry et al.
1970). Although the acetylation polymorphism itself does not appear
to be associated with any HLA haplotype (Batchelor et al. 1980),
potential associations between other HLA haplotypes and different
pharmacogenetic polymorphisms remain to be established end merit
study.
OTHER PHARMACOGENETIC AREAS OF INVESTIGATION
Intriguing pharmacogenetic observations that require further study
include increased sensitivity of certain ethnic groups to ethanol
(Wolff 1972), mydriatic agents (Chen and Poth 1929), and
diphenhydramine (Spector et al. 1980). In cultured cells, amplifi-
cation of specific DNA sequences correlates highly with resistance
to certain cytotoxic drugs, such as adriamycin (Roninson et al.
1984); elaboration of the mechanisms for this gene-environment
interaction requires elucidation of the nature of the proteins
encoded by the amplified DNA. These and other examples indicate the
wide variety of ways in which genetic constitution can influence
drug response. The pharmacogenetic approaches described above could
be applied with the modifications described at the outset of the
chapter to elucidate large interindividual variations that occur in
response to certain drugs of abuse. Probably similar principles
pertain and results of such studies could be informative and
therapeutically useful.
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Studies on an Animal Model of
Alcoholism
Ting-Kai Li, M.D.; Lawrence Lumeng, M.D.; William J.
McBride, Ph.D.; Marshall B. Waller, Ph.D., and James M.
Murphy, Ph.D.
INTRODUCTION
Alcoholism is a disorder characterized by a persistent and pro-
gressive pattern of aberrant alcohol-seeking behavior which,
over time, results in the loss of control over drinking and the
development of tolerance and physical dependence. As discussed
by Dr. Cloninger in this monograph, there is noW strong evidence
that genetic predisposition plays an important part in the
development of alcoholism in many people. Accordingly, the
identification of biological risk factors and their underlying
mechanisms of influence has become a high priority area of
alcohol-related biomedical research for the present and the
future.
It is noteworthy that there already exists a considerable body
of evidence both in humans and in experimental animals that a
variety of behavioral, physiological, and biochemical responses
to ethanol have genetic determinants. Alcohol drinking behavior
or preference is one such response (McClearn and Rodgers 1959;
Eriksson 1968; Li et al. 1979). Others include central nervous
system (CNS) (McClearn and Kakihana 1973; Riley et al. 1977) and
systemic sensitivity (Mizoi et al. 1979) to ethanol, alcohol
metabolizing capacity (Kopun and Propping 1977; Thurman 1980),
the acquisition of tolerance to ethanol (Grieve et al. 1979),
and the development of physical dependence on ethanol (Goldstein
1973). One experimental approach to gaining an understanding of
biological predisposition would be to study how these other re-
sponses to ethanol relate genetically and mechanistically to
normal and abnormal drinking behaviors. The validity of this
approach is supported by recent reports that individuals who
have the alcohol-flush reaction, caused by an abnormal elevation
of circulating acetaldehyde, are less prone to becoming alco-
holic than those who do not (Harada et al. 1983; Yoshihara et
al. 1983). Activity of the low Km aldehyde dehydrogenase
isozyme is absent in tissues of individuals with this inherited
trait, rendering then intolerant to the consumption of even
small to moderate amounts of ethanol.
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Investigators are searching for biological markers and potential
mechanisms of genetic influence in children of alcoholics, who
are a high-risk population. Dr. Schuckit reports his research
on phenotypic markers in sons of alcoholics elsewhere in this
monograph. The study of the relationship of alcohol drinking
behavior to other heritable responses to ethanol in experimental
animals requires the ready availability of animals willing-to
self-administer large amounts of ethanol. This feature is con-
sidered by most investigators to be a key element of any animal
model for alcoholism. It is well known that most experimental
animals avoid drinking ethanol solutions that are 10% (v/v) or
higher in concentration when food and water are concurrently
available. However, some strains of outbred laboratory rats do
show a wide range of individual variation in alcohol preference
and lines of rats exhibiting high and low alcohol preference
have been raised through bidirectional selection (Eriksson 1968;
Li et al. 1979). These successful breeding efforts have served
to substantiate the existence of genetic influence on alcohol-
seeking behavior, as have also the finding of differences in
alcohol preference among inbred mouse strains (McClearn and
Rodgers 1959). One line of alcohol-preferring rats, the P line,
has now been systematically characterized with respect to its
drinking behavior. The data indicate that it satisfies virtu-
ally all the preceived requirements for an animal model of alco-
holism. Comparison of the effects of ethanol on P rats and on
NP rats, a line simultaneously selected for alcohol nonprefer-
ence (aversion), has revealed differences that should provide
insights into the biological basis of aberrant alcohol-seeking
behavior. This chapter reviews the work performed on these
selectively bred lines.
DEVELOPMENT OF AND STUDIES ON THE P AND NP LINES OF RATS
The suggested essential requirements of an animal model of alco-
holism are (Lester and Freed 1973):
1.
2.
3.
4.
5.
Ethanol should be self-administered orally, in prefer-
ence to water or other solutions having the same
caloric: value and palatibility.
The amount consumed should produce measurable blood
alcohol. concentrations (BACs).
Ethanol should be positively reinforcing, i.e., the
animals should be willing to overcome obstacles or work
to obtain the alcohol.
The positive reinforcing effect of ethanol should be
accountable in large part, if not entirely, by the CNS
pharmacological actions of ethanol or its metabolic
products and not because of its caloric value, taste,
or smell.
Consumption should lead ultimately to
a) repeated episodes of intoxication,
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b) tolerance, and
c) physical dependence.
The P and NP lines were developed by selective breeding for high
and low alcohol preference from a foundation stock of Wistar
rats (Li et al. 1981). Testing was performed with an unflavored
10% (v/v) solution of ethanol made continuously available in a
Richter tube to individually housed animals. Water in an iden-
tical Richter tube as an alternate source of fluid and solid
food were provided ad libitum. The amounts of 10% ethanol,
water, and food consumed daily were measured for 3 weeks and
those animals exhibiting the highest and lowest consumption
scores (g ethanol/kg body weight/d), respectively, were mated to
start the next generation of P and NP lines. After 20 genera-
tions, the consumption scores (g/kg/d; mean ± SD) were: P
males, 5.5 ± 1.2; P females, 7.3 ± 1.7; NP males, 1.1 ± 0.6; NP
females 1.0 ± 0.9. The P and NP animals in the current S26
generation display similar characteristics. The P rats on test
consume between 20% and 30% of the total calories as ethanol. They
substitute the ethanol calories for a part of the food calories
and gain weight at the same rate as control animals not given
the ethanol solution as a fluid choice.
The P rats drink about 70% of the ethanol in the dark, when they
also eat most of the food. Drinking occurs in bursts at irregu-
larly spaced intervals (Waller et al. 1982a). When blood is
sampled during the dark cycle, e.g., at the 3rd and 11th hours,
BACs ranging from 14 to 120 mg% have been obtained. Mean values
are about 60 mg%. When BACs are measured 30 minutes after the
completion of drinking episodes, as determined by a drinkometer,
values of 52 to 124 mg% have been obtained. The mean is 86
mg%. Clearly, these animals are attaining systemic alcohol con-
centrations that are pharmacologically active, at least for
humans. Studies have also been performed to determine what BACs
coincide with cessation of drinking and what blood levels pro-
duced by intravenous infusion would lead to curtailment of oral
intake (Waller et al. 1982b). It was found that 50 to 70 mg%
did both. It appears, therefore, that the higher BACs attained
with oral intake represent overshoot, caused by delayed gastro-
intestinal absorption.
The P rats will work in order to obtain ethanol through operant
responding (Penn et al. 1978). Free-feeding male animals were
trained to bar-press for sweetened milk in a dipper as reward
and the milk was then replaced with 10% ethanol. With food and
water constantly available, they bar-pressed for the ethanol
both on a continuous reinforcement schedule and when the bar-
press to reinforcement ratio was increased. In fact, the re-
sponse to reinforcement ratio could be raised to 6 or 7 before
water intake increased, yielding a response rate of over 1,000
bar-presses/24 hours in each of the animals tested. Since food
and water were freely available to the animals, it appears un-
likely that the P animals found the ethanol solutions rewarding
because of caloric needs or thirst.
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The above studies, however, do not distinguish whether the rein-
forcing properties of ethanol are its pharmacological effects or
its taste and smell. To dissociate the post-ingestive effects
of ethanol from its orosensory cues, intragastric self-adminis-
tration experiments were performed, using an experimental design
similar to that reported by Deutsch and coworkers (Deutsch and
Hardy 1976; Deutsch and Walton 1977). Male P and NP animals
were surgically implanted with transesophageal catheters for the
intragastric delivery of fluids. Following recovery, the
animals were trained to associate: a) the intragastric delivery
of ethanol with the drinking of a neutral-flavored (almond or
banana) water solution contained in a U-shaped drinking tube;
and b) the intragastric delivery of water with the drinking of
the other neutral-flavored solution in another U-tube. The
drinking of the fluids from the U-tubes activated a pump to
deliver an equal volume of either the water or the ethanol solu-
tion intragastrically. After training, the animals were pre-
sented with both U-tubes and allowed free-choice drinking of the
two flavored solutions on a 24-hour availability schedule. Food
was freely available throughout the experiment. It was found
that the P rats consistently self-infused greater volumes of the
ethanol solution and lesser volumes of the water than did the NP
rats (Waller et al. 1984a). ThiS difference was observed re-
gardless of whether the concentration of infused ethanol was 10%,
20%, 30%, or 40%. The amount of ethanol infused by the NP rats
was always less then 1 g/kg/d at all concentrations of ethanol
tested. By contrast, the amount of ethanol infused by the P
rats increased from 3.0 ± 0.3 g/kg/d with 10% ethanol to 9.4 ±
1.7 g/kg/d with 40% ethanol. The BACs of animals measured 30 to
40 minutes after observed episodes of self-infusion of 20%
ethanol were 116 to 303 mg% (mean of 199 mg%) and, with the
self-administration of 40% ethanol, BACs were 92 to 415 mg%
(mean of 231 mg%). All animals repeatedly showed signs of in-
toxication, such as ataxia and somolence, after intragastric
ethanol self-administration. These blood ethanol levels
attained with intragastric self-administration were considerably
higher than those observed in the P rats with free-choice drink-
ing. Interestingly, although the total amount of 40% ethanol
self-infused per day was significantly higher than the pretested
voluntary oral consumption scores of the P rats (6.5 g/kg/d), the
amount of 20% and 30% self-infused (5.8 and 7.3 g/kg/d, respec-
tively) was not.
The above results are consistent with the notion that the post-
ingestive, pharmacological actions of ethanol are rewarding to
the P rats, but are aversive to the NP rats. However, the
difference in BACs attained by the P rats with free-choice oral
consumption and with intragastric self-administration suggests
that orosensory cues also may be an important modulator of the
amount of ethanol self-administered per drinking episode. It is
important to note that Deutsch and coworkers (Deutsch and Eisner
1977; Deutsch and Walton 1977) were able to demonstrate intra-
gastric self-administration of ethanol in large amounts in rats
unselected for ethanol preference only if they were first made
physically dependent by the prior forcible administration
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of ethanol. Ethanol self-administration behavior
was quickly extinguished in maelected animals not made ethanol-
dependent, as was observed also in our study with the NP rats.
In contrast, the P animals in this study were not made dependent
on ethanol and, in fact, were ethanol-free for at least a month
before these experiments. Clearly, the innate ethanol prefer-
ence of experimental animals is an important if not crucial
variable in studies of ethanol self-administration.
With chronic free-choice drinking of 10% ethanol, the P rats
develop metabolic tolerance. After 6 weeks, the ethanol elimi-
nation rate of ethanol-consuming animals was 15% higher than
that of control animals. Weight gain and total caloric intake
of the animals in the two groups were identical. Ethanol
represented 22% (week 1) to 30% (week 6) of the total calories
consumed daily by the experimental group. The degree of meta-
bolic tolerance developed over this period with free-choice
drinking was the same as that developed by P rats forcibly given
a total liquid diet in which 35% of the total caloric content
was derived from ethanol (AIN liquid diet containing 5%
ethanol). Studies are in progress to determine the time course
and extent of neuronal tolerance development with free-choice
drinking by the P rats.
We have also examined whether chronic free-choice drinking by
the P rats produces physical dependence (Waller et al. 1982a).
Experimental animals were given constant access to 10% ethanol
and water for 20 weeks, while control animals received only
water. Food was available ad libitum. After 20 weeks, the
ethanol solution was taken away from experimental animals
and both groups were scored for signs of withdrawal by a blinded
observer. In the first 24 hours following removal of ethanol,
18 of the 19 ethanol-exposed animals exhibited signs of with-
drawal. These included Straub tail, broad based gait, tremu-
lousness, hyperactivity, wet dog shakes, teeth chattering, in-
duced running, and bizarre behavior. These manifestations
abated after 72 hours. As expected, none of the control animals
showed withdrawal signs. We concluded, therefore, that chronic
free-choice drinking of 10% ethanol can produce physical depen-
dence in the P rats.
The studies summarized above indicate that the P line of selec-
tively bred rats should be a useful animal model for exploring
the biology of alcohol-seeking behavior and conditions that
promote and lessen this kind of behavior. lb this end, we have
performed a number of studies comparing the P and the NP lines.
One way in which the lines differ is the degree of motor impair-
ment produced by moderate to high doses of ethanol. In these
studies, the animals were trained to jump onto a descending
platform in order to avoid foot shock. The height to which the
animals can jump was used as the measure of their motor perfor-
mance. It was found that the NP rats took much longer to recover
from the sedative-hypnotic effects of ethanol than did the P
rats (Lumeng et al. 1982). This difference could not be
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attributed to a difference in alcohol elimination rate between
the lines nor to a difference in CNS sensitivity to ethanol.
Rather, it was because the NP rats took longer to develop toler-
ance than did the P rats. This could be assessed by use of the
jump test after the administration of a second dose of ethanol
and the comparison of BACs at the time of recovery to criterion
performance after the first and the second dose. It was found
that, while both the P and NP rats developed acute tolerance,
the P rats did so more quickly or to a greater degree than did
the NP rats (Waller et al. 1983).
Although rapid tolerance development might be a mechanism that
promotes and sustains high levels of consumption, it is unlikely
to be a primary determinant of alcohol preference, since the
BACs attained during free-choice drinking, usually less than 150
mg%, are substantially lower than those produced in the studies
of tolerance development described above. Accordingly, a basis
for the difference in drinking behavior between the P and NP
rats was sought at lower doses of ethanol. It was found that
the P rats exhibit increased spontaneous motor activity (SMA)
following the intraperitoneal injection of ethanol, 0.065 to 0.5
g/kg. By contrast, the NP rats do not show stimulation, and
decreased SMA began to occur with doses of 0.5 to 1.5 g/kg. The
increase in SMA in the P rats is as much as 50% with 0.25 g/kg
doses of ethanol. (Waller et al. 1984b).
The combination of low-dose stimulation by ethanol and acute
tolerance development to the high-dose effects offers an attrac-
tive hypothesis of alcohol abuse. This hypothesis assumes that
the low-dose stimulation observed in the P rats is a reflection
of the positively reinforcing or rewarding features of ethanol
consumption, whereas the high-dose depressant effect is aversive
and inhibits drinking. As tolerance to the high-dose effects of
ethanol develops, the rewarding actions of ethanol become
progressively extended into the higher dosage range, leading to
increased consumption. We are currently testing this hypothesis
in the P line of rats.
Studies have also been performed to discern whether there are
neurochemical differences between the P and the NP rats. A
major discovered difference is in the regional brain content of
serotonin. Ethanol-naive P rats consistently have lower levels
of serotonin in the cerebral cortex, corpus striatum, thalamus,
hypothalamus, and hippocampus, and lower levels of 5-hydroxy-
indole acetic acid in the cerebral cortex and hippocampus, than
do NP rats (Murphy et al. 1982). Although the significance of
these neurochemical differences with respect to ethanol drinking
preference is yet unclear, it is intriguing that serotonin and
norepinephrine reuptake inhibitors are effective in reducing
voluntary ethanol consumption in rats (Amit et al. 1984). These
drugs display a similar action in the P rats, both on the
24-hour free-choice oral consumption schedule (Murphy et al.
1984) and with intragastric ethanol self-administration.
Clearly, we are interested in the specificity of this kind of
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response in relationship to the postulated roles of serotonin
and/or norepinephrine in the reinforcing actions of ethanol.
SUMMARY
Past and ongoing studies indicate that the selectively bred P
line of rats satisfies virtually all the suggested criteria for
an animal model of alcoholism. They attain pharmacologically
active levels of BAC and develop tolerance and physical depen-
dence with voluntary oral ethanol ingestion, while in the free-
feeding state. Ethanol is positively reinforcing to the P rats
and consumption appears to be directed by the post-ingestive,
pharmacological effects of ethanol, as revealed by the intra-
gastric self-administration studies.
Sane interesting differences between the P and the NP lines have
been uncovered. They differ in the content of serotonin in
several brain regions and they respond differently to ethanol.
The P rats develop acute tolerance to sedative-hypnotic doses of
ethanol more rapidly than do the NP rats, and they exhibit stim-
ulation with low doses of ethanol. These differences suggest
hypotheses on mechanisms underlying alcohol-seeking behavior
which can now be tested experimentally.
It should be emphasized, however, that the described findings
are the product of but a single genetic experiment. Clearly,
replication is needed, and we are currently doing this, using a
better defined, heterogeneous stack of rats. This one experi-
ment, however, has demonstrated the feasibility of developing
animal models of alcoholism and offers hope that the genetic
and biological basis of alcohol-seeking behavior can be explored
in the laboratory. The screening and testing of pharmacological
agents able to deter alcohol-seeking behavior is an obvious
practical application of this model.
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Development of DNA Probes to
Investigate Genetic Variation of
Alcohol Metabolizing Enzymes
Moyra Smith, M.D., Ph.D.; Gregg Duester, Ph.D.; and G.
Wesley Hatfield, Ph.D.
INTRODUCTION
Alcohol dehydrogenase (ADH) is responsible for the oxidation of a
wide variety of primary, secondary, and aromatic alcohols, but is
most noted as being the enzyme primarily responsible for oxidizing
ethanol to acetaldehyde. Human ADH exists as a set of at least 15
different isoenzymes that differ in electrophoretic mobility, sub-
strate affinities, and inhibition characteristics (Smith et al.
1973; Li 1977; Pares and Vallee 1981). All isoenzymes are similar
in that they are dimeric, each monomer having a molecular weight of
approximately 40,000 daltons. The various isoenzymes are categorized
into three classes. Class I contains a large group of isoenzymes
possessing various combinations of -ADH subunits coded by
three gene loci: ADH1, ADH2, and ADH3, respectively. Class II con-
tains the ADH isoenzyme (Bosron et al. 1979; Li and Magnes 1975).
Class III contains the x-ADH isoenzyme, which oxidizes high molecu-
lar weight alcohols, but not ethanol (Pares and Vallee 1981).
Class I and II are primarily liver-specific enzymes, although small
amounts of activity of these isoenzymes occur in intestine, kidney,
and lung (Smith et al. 1971). Class III ADH is a constitutive
enzyme and is found in all cell types. Studies on the gene products
of human class I ADH genes have revealed genetic polymorphisms.
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Common genetic variation occurs at the ADH2 and the ADH3 gene
loci. One of the variant forms of ADH2 is known to give rise
to an altered ADH which differs in its kinetic properties and
is implicated in differences in alcohol tolerance. The exact
role of genetic variation in relation to propensity to develop
alcoholism have been difficult to assess since this enzyme is
primarily a liver-specific enzyme and is not readily analyzable
in accessible tissues such as blood cells or serum.
We have initiated a research study aimed at isolating ADH and
aldehyde dehydrogenase (ALDH) genes so that molecular probes
may be derived to analyze genetic variation in the ADH and
ALDH genes and their flanking regions. The results presented
here relate to the derivation of DNA probes for the class I
ADH genes.
Availability of partial amino acid sequence data for the ß-ADH
isozyme, coded by the ADH2 gene, enabled us to select a sequence
of five amino acids with relatively low code degeneracy, near
the carboxy terminal region of the ADH polypeptide. An oligo-
nucleotide probe corresponding to this sequence was commercially
obtained. The probe consisted of a mixture of 16 different
oligomers, one of which is perfectly complementary to ADH mRNA
(figure 1). The radiolabeled oligonucleotide probe was used to
screen colonies derived from the adult human liver cDNA library
of Orkin (Woods et al. 1982).
FIGURE 1
SEQUENCE OF OLIGONUCLEOTIDE PROBE (14 mer) FOR HUMAN ADH
One clone isolated from the cDNA library and designated pADH12
was found to contain an insert of 1100 base pairs. A restric-
tion map of this clone was derived by further digesting the iso-
lated cDNA insert by various enzymes. Restriction fragments
were then cloned into the M13 bacteriophage and sequenced
(Duester et al. 1984). Analysis of the DNA sequence of the in-
sert in the pADH12 clone revealed that it contained a 593 base
pair 3' untranslated region in addition to a 273 base pair
translated region coding for 91 amino acids. The DNA sequence
in this region predicted exactly the amino acid sequence of the
terminal 91 amino acids in ß-ADH as derived by Bühler and
coworkers (1984).
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This pADH12 cDNA clone has been used to derive genomic ADH clones.
The Maniatis library of human DNA in lambda phage was screened
with pADH12. Information from peptide mapping studies (Strydom
and Vallee 1982) and partial sequence information on the ADH3
polypeptide (Bühler et al. 1984) indicate that the coding
regions of the three class I ADH genes are closely homologous.
Using radiolabeled pADH12 as a probe under conditions of low
stringency, it should be possible to isolate from libraries of
human genomic or cDNA, clones corresponding to all three class I
ADH genes. One of the genomic clones, which was isolated from
the Maniatis library using pADH12, has been found to contain a
terminal exon, which is similar but not identical to that in pADH12 in
addition to an adjacent intron and 3' untranslated region
(Duester 1984). The base modifications present in the exon of
the ADH53 clone correspond to those which one would expect to
find in the ADH1 gene, based on the amino acid differences
between ß-and ADH polypeptide as determined by Jörnvall
(personal communication, 1984)
INVESTIGATION OF ADH GENETIC VARIATION USING THE pADH12 AND
THE ADH53 PROBES
Prior to using the ADH53 clone in studies of human DNA poly-
morphism, we ascertained that this clone did not contain any
repetitive DNA sequences. Human DNA was isolated from periph-
eral blood leukocytes or from cultured hymphoblastoid cells.
Human DNA was digested with a number of different restriction
endonucleases, and individual DNA digests were subjected to
agarose gel electrophoresis and Southern transfer to nitro-
cellulose filters (Southern 1972). Filters were hybridized
with radiolabeled ADH gene probes and then washed at different
stringencies prior to autoradiography. The restriction endo-
nuclease MSP 1 has thus far proved most useful for detecting
DNA polymorphism in the ADH genes (figure 2).
FIGURE 2
MSPI FRAGMENTS OF HUMAN GENOMIC DNA REVEALED BY HYBRIDIZATION
TO ADH53 PROBE
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Using the ADH53 probe and a low-stringency wash of the filters
(1 x SSC, at 55 C for 40 minutes), four or five MSP 1
fragments are seen. These fragments are 12.5, 10.0. 8.6, 6.8,
and 3.8 Kb in size (see figure 2 and figure 3). Occasional
individuals have also been found to have a 4.2 Kb fragment.
Following a high-stringency wash (0.1 x SSC/65 C/30
minutes) only the 10.0, the 8.6, and the 3.8 Kb fragments
remain, suggesting that these fragments are most analogous to
the ADH53 probe, which probably represents the ADH1 gene.
Using the pADH12 probe, 4 fragments may be seen. These are
the 12.5, 10.0, 8.6, and 6.8 Kb fragments. However, the 6.8 Kb
fragment is frequently very weak with pADH12. Following a high-
stringency wash, the 8.6 Kb fragment is the only fragment still
visualized, suggesting that this fragment is most analogous to
the ADH2 gene (see figure 3).
FIGURE 3
CHANGES IN PATTERNS OF DNA FRAGMENTS WHICH HYBRIDIZE TO ADH53 AND
ADH12 UNDER CONDITIONS OF LOW AND HIGH STRINGENCY
In occasional individuals, an 11 Kb band may be visualized. This
fragment is apparently more analogous to ADH2, based on the
observation that it is usually more intense with pADH12 than with
ADH53. The 12.5 Kb MSP 1 fragment hybridizes equally well with
pADH12 and ADH53 at low stringency. At high stringency, it is not
present with either probe. This finding suggests that the 12.5 Kb
fragment may be derived from a third class I ADH gene, possibly
the ADH3 gene which codes for the polypeptide. Individual vari-
ation has been observed with respect to the number of MSP 1 frag-
ments. In some individuals, the 12.5 Kb fragment is absent, while
in other individuals the 10.0 Kb fragment is absent (see figure 2).
Individual variation has also been observed with respect to the
relative intensity of the different fragments (see figure 4).
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FIGURE 4
PERSON TO PERSON DIFFERENCES IN THE RELATIVE INTENSITIES OF THE
DNA FRAGMENTS WHICH HYBRIDIZE TO THE ADH53 PROBE
Based on differences in the relative intensity of the MSP 1
fragments and on the fragment size differences in different
individuals, we have drawn up the following hypothesis. One
of the class I ADH genes (probably ADH3) gives rise to an
MSP 1 fragment which hybridizes to ADH53 and pADH12 and is
12.5 Kb. A polymorphic site exists so that in some individuals
a 10.0 Kb fragment results. However, the additional 2.5 Kb
fragment which arises as a result of this polymorphism may not
be visualized with ADH53 or pADH12. A second ADH gene (probably
ADH1) gives rise to a 6.8 Kb fragment. In certain individuals
an MSP 1 site is absent so that a 10.0 Kb fragment results.
Individuals who are doubly heterozygous at the two loci described
above will therefore exhibit a very intense 10.0 Kb fragment.
Examination of MSP 1 digestion patterns in a number of nuclear
families has provided evidence of heritability of certain frag-
ments. In figure 5a, the mother is homozygous for the 10.0 Kb
fragment, while the father is homozygous for the 12.5 Kb frag-
ment. Their son is an obligate heterozygote, having inherited
the 12.5 Kb fragment from his father and the 10.0 Kb fragment
from his mother.
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FIGURE 5
ADH53 HYBRIDIZING MSP 1 FRAGMENTS PRESENT IN DNA FROM INDIVIDUALS
IN 3 NUCLEAR FAMILIES
In figure 5c the father and the mother were both homozygous for
the 10.0 Kb fragment. Their two sons were homozygous since each
inherited the 12.5 Kb fragment from their mother and father. Note
that in figures 5a and 5b there is also evidence of polymorphism
with respect to the 3.8 and 4.2 Kb fragments. The exact relation-
ship of this variation and the 12.5 to 10.0 Kb fragment variation
is not clear at present. We have thus far examined DNA from 101
individuals, including 80 Caucasoids, 10 Orientals, and 11 Ne-
groids. Polymorphism has been demonstrated in each population group.
In the analytical system described above, the presence of an MSP 1
fragment 10.0 Kb in size could result from polymorphism of either
the ADH1 or the ADH3 gene. In an attempt to further resolve this
polymorphism, we are currently carrying out double digestions of
human DNA with EcoRI and MSP 1. In addition, studies are being
carried out to derive gene-specific probes and/or gene-specific
hybridization conditions. Further studies are also required to
define the origin and significance of the 11 Kb band which occurs
in occasional individuals and which is apparently more intense
with the pADH12 (i.e., the ADH2) gene probe.
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Genetics as a Tool for Identifying
Biological Markers of Drug Abuse
Allan C. Collins, Ph.D.
A search for biological markers of drug abuse or
alcoholism presupposes that some link can be made
between the effects of behaviorally active drugs and
some biochemical factor that is found in readily ac-
cessible tissues. Presumably, the identification of
biological markers would be of value in that especial-
ly susceptible individuals could be diagnosed and
warned of potential consequences of drug use.
The identification of a biological marker involves a
search for some biological substance(s) which may be
correlated with the biological substrates for drug
dependence. Such a search requires, as a precondition,
that drug dependence is due, at least in part, to
biological factors. Since biological factors (en-
zymes, proteins, metabolic intermediates, anatomy) are
regulated by genes, the search for a biological marker
for drug abuse or alcoholism is essentially a search
for gene products that are directly linked to or
regulated by those genes that affect drug abuse re-
lated behavior. The search for such markers will be
successful only if variation exists within the popula-
tion with regard to drug abuse related behaviors.
Presumably, variation will also exist within the popu-
lation for some substance that is related to “drug
abuse genes.” Only if variation in susceptibility to
alcoholism or drug abuse exists does it make sense to
attempt to identify potential markers for these condi-
tions.
The biological marker need not be influenced directly
by those genes that influence drug abuse. An adequate
marker could be the product of a gene that is closely
linked to the drug abuse genes. Alternatively, pleio-
tropic effects of drug abuse genes may prove to be
valuable markers. Pleiotropy is seen when a single
gene influences more than one phenotype or trait.
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Thus, the search for a biological marker may be a
search for some gene product(s) that is directly re-
lated to drug abuse, a search for gene products that
are regulated by pleiotropic effects of drug abuse
genes, or a search for the products of genes that are
closely linked to the drug abuse genes.
The evidence that supports the notion that genetic
factors contribute to the development of alcoholism in
humans is substantial and is reviewed in other chap-
ters in this monograph. On the other hand, the evi-
dence that indicates other forms of substance abuse
are influenced by genetic factors is lacking--not
because studies have been carried out that indicate
that drug abuse is not influenced by hereditary
factors but, rather, because in depth studies have not
been carried out to assess this question. This sug-
gests that a search for biological markers for alco-
holism might be successful if initiated in the near
future because appropriate populations may be more
readily identified. On the other hand, a search for
biological markers of drug abuse may be premature
since the identification of adequate human populations
for drug abuse may not be possible.
ANIMAL MODELS
A potential solution to the problem of lack of avail-
ability of suitable human populations for study is to
develop animal models. This approach has been quite
successful in alcohol research, and a number of genet-
ically defined animal models related to alcoholism are
now available. The progress related to the develop-
ment of genetically defined animal models of drug
abuse is considerably less, although enough data are
currently available to indicate that successful models
could be obtained. This chapter describes some of the
progress that has been made in identifying potential
models and also makes recommendations as to how animal
models can be used to aid in the identification of
biological markers of drug abuse.
The advantages of animal models in the search for
biological markers of drug abuse and alcoholism are
numerous. Perhaps the most important of these advan-
tages relates to the potential need for invasive
testing. Drug abuse and alcoholism are, in all like-
lihood, influenced to a major degree by central
nervous system factors. Therefore, some factor(s) in
brain are likely to be of primary importance in de-
termining susceptibility to these afflictions. For
example, it may be that the amount of drug receptor in
specific brain regions is critical in determining
whether an individual will be more likely to abuse the
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drug which affects this receptor. Obviously, the
availability of human brain tissue is not sufficient
to test easily any hypothesis which requires measuring
the brain content of some biological factor. It might
take years, for example, to test the hypothesis that
greater or lesser numbers of brain opiate receptors
promote the abuse of opiates. Research involving
humans would be totally impossible if the factor which
regulates "addictability" is the degree of change in
some neurochemical parameter, such as receptor number,
during chronic drug use. Animal models can be of
value in testing such hypotheses as well as in an
efficient systematic search for gene products which are
related to those genes that regulate changes in
receptor number during chronic drug treatment.
If an animal model of drug abuse is to be developed,
consideration must be given to what the model should
represent. Should the model encompass every aspect of
drug-related behavior or should it attempt to emulate
only specific aspects? A complete animal model of
human drug abuse might not be attainable. However, it
should be possible to develop models of specific as-
pects of the total human condition. For example, it
may be possible to identify or develop genetic stocks
of animals that differ in avidity for specific drugs,
initial sensitivity, tolerance development, and se-
verity of a withdrawal syndrome. Once these models
have been developed, they can be used to test hy-
potheses relevant to the mechanisms underlying the
differences in avidity, sensitivity, etc., as well as
being of value in the search for biological markers.
The prerequisite for identifying a biological marker
for drug abuse is that some aspect of drug dependence
is influenced by genetic factors. Therefore, it seems
reasonable to suggest that the first step that should
be taken is to ascertain whether genetically influ-
enced variation exists in appropriate animal popula-
tions. In this regard, perhaps the easiest approach,
because of the relative availability, is to screen
inbred strains for differences in the phenotype\
(trait) of interest.
Inbred Strains
Inbreeding is achieved by mating closely related in-
dividuals. In commonly available rodent stocks, this
has generally been achieved by brother-sister matings.
Inbreeding leads to an increase in genetic uniformity
within a strain, and after approximately 20 generations
of inbreeding a strain can be considered genetically
uniform; homozygosity will have been attained at all
loci with the possible exception of those alleles
which are carried on the sex chromosomes. The process
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of inbreeding is nondirectional. Alleles are fixed in
a particular configuration by chance with the excep-
tion of those traits that are related to reproductive
fitness. Any differences found between inbred strains
are fortuitous. In addition, no assurance can be made
that a given inbred strain will have in its genome all
of the genes that influence a drug-related behavior.
Indeed, in view of the fact that most inbred rat and
mouse strains can be traced to a smell number of
animals, in some cases two, it is highly probable that
any strain will have only a sampling of all of the
possible alleles that will affect a trait of interest.
A highly recommended approach regarding the use of
inbred strains is to screen a number of strains. A
relationship between two traits in a given strain may
be unique. However, if this relationship is seen in a
number of strains, it is more likely that these two
traits are associated genetically. A major advantage
of inbred strains is their constancy over time and in
different laboratories. Such constancy increases
experimental reliability and may allow collaborative
studies that are carried out at different locations,
thereby facilitating the screening of a large number
of strains.
A classic example of consistent findings within inbred
strains is the alcohol preference of various mouse
strains; a number of investigators have noted that
C57BL mice uniformly prefer ethanol-containing solu-
tions, whereas DBA mice avoid ethanol-containing
drinking fluids (McClearn and Rodgers 1959; Russell
and Stern 1973; Randall and Lester 1975; Pickett and
Collins 1975). Strain differences with respect to
other alcohol-related behaviors have also been well
documented. Included among these are strain differ-
ences in acute sensitivity to the effects of ethanol
on locomotor activity (Randall et al. 1975; Oliverio
and Eleftheriou 1976), passive avoidance conditioning
(MacInnes and Uphouse 1973), body temperature (Moore
and Kakihana 1978; Crabbe 1983), and duration of
ethanol-induced loss of the righting response (sleep
time) (Kakihana et al. 1966; Damjanovich and MacInnes
1973; Crabbe 1983). Strain differences in the devel-
opment of tolerance to ethanol have also been des-
cribed (Moore and Kakihana 1978). as have strain dif-
ferences in the severity of an ethanol withdrawal
syndrome (Kakihana 1979; Crabbe et al. 1983). The
vast majority of the research relating to strain
analyses has been descriptive in nature. Very few of
these studies have attempted to determine such funda-
mental parameters as dominance relationships or an
estimate of the number of genes involved in regulating
the trait being measured; nor have the majority of
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these studies attempted to provide biological explana-
tions for these strain differences in ethanol-related
behaviors. Clearly, very few of the studies concern-
ing strain differences in alcohol- related behaviors
have attempted to identify a marker that could be of
value in predicting differential sensitivity to the
trait being studied.
Strain differences in response to drugs of abuse have
also been reported. For example, strain differences
in response to amphetamines (Anisman 1975; Anisman and
Kokkinidis 1975; Bovet and Oliverio 1967), nicotine
(Morrison and Lee 1968; Hatchell and Collins 1977;
Marks et al. 1983; Miner et al. 1984), ha1lucinogens
(Lush 1975; Tilson et al. 1975), benzodiazepines
(Rambert et al. 1976), barbiturates (Randall and Les-
ter 1974; Belknap et al. 1973), and opiates (Castel-
lano and Oliverio 1975; Horowitz 1976; Collins et al.
1977) have been reported. In general, these studies
have involved examinations of different mouse or rat
strains and have investigated strain differences in
acute responses to these drugs. However, some of
these studies have assessed strain differences in drug
self administration (Horowitz 1976) or severity of a
withdrawal syndrome (Belknap et al. 1973). As is
the case with the research done in the alcohol field,
few of these investigations have attempted to estimate
gene number or dominance relationships and absolutely
no concerted attempt has been made to identify poten-
tial biological markers. Nonetheless, the fact that
strain differences have been identified argues that
genetic factors are important in regulating response
to drugs of abuse in animals. This finding supports
the assumption that biological markers might be found.
Genetic Crosses
Once inbred strain differences in a drug-related re-
sponse have been identified, genetic crosses can be
developed. Such crosses can be invaluable in testing
hypotheses of interest. For example, it seems highly
likely that inbred strains which differ in some trait
of interest could be identified. These strains will
likely differ in a number of traits. Segregation
analysis can be used to test the association between
traits. Inbred strains could be crossed to obtain the
first filial (F1) generation. If a number of strains
are intermated in all possible ways, a diallel
analysis can be made. Such an analysis allows an
estimate of dominance relationships. Once the F1
generations have been obtained, these animals can be
intermated to obtain the F2 generation. The F2 gen-
eration is invaluable for assessing linkage in that
genes which are not closely linked will segregate in a
quasi-independent fashion into the F2 generation.
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Pickett and Collins (1975) used such an analysis to
investigate the relationship between ethanol prefer-
ence and brain serotonin content. Examples of other
investigations that have used F1 analyses to investi-
gate genetic regulation include studies of the effects
of morphine on activity (Shuster et al. 1973; Castel-
lano and Oliverio 1975) and the effects of amphetamine
on activity (Bovet and Oliverio 1973). None of these
studies have attempted to identify biological markers
for the drug-induced behaviors being studied. How-
ever, the potential for such studies seems highly
promising.
Recombinant Inbred Strains
Perhaps the moat powerful tool currently available to
test the relationship between two or more traits is
recombinant inbred strains. Recombinant inbreds are
constructed by first developing an F2 or preferably
the F3 or F4 generations derived from crossing two
inbred strains. Brother-sister mating is initiated in
these foundation stocks. As was the case with inbred
strains, genetic uniformity is achieved as inbreeding
proceeds. The F3 or F4 generations are recommended as
the foundation stock rather than the F2 because a
maximum reshuffling of genes is obtained. Linkage is
broken down and only genes that are very closely
linked wi11 be found in association with one another.
This, of course, would be a very desirable trait for a
biological marker. In theory, an F3 or F4 generation
could serve as an adequate test group for a correla-
tional analysis. However, since each animal is ge-
netically unique, any variance involved in measuring
the traits of interest will affect the correlation
detected. For many traits, it may be desirable to
have a test population where replicate samples can be
obtained. Recombinant inbreds are ideal for such a
situation because replicate samples can be obtained
from each recombinant inbred stock. Any variance seen
within each recombinant inbred provides an estimate of
environmental influence on the traits of interest.
In view of the fact that recombinant inbreds are
selected from F3 or F4 stocks derived from two inbred
strains, these animals should be invaluable in testing
linkage relationships. If two traits of interest are
found in association in the parental inbreds and none
of the recombinant inbreds demonstrate this associa-
tion, it can be assumed that the traits were not
closely linked in the originating inbred strains. If
some, but not all, of the inbreds exhibit the traits
of interest, it can be assumed that the genes which
regulate these traits are closely linked. If 100% of
the recombinant inbreds demonstrate both traits, iden-
tity of genetic control, pleiotropy, or extremely
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close linkage probably explain the genetic relation-
ship. Because knowledge of the precise genetic rela-
tionship between traits of interest would be invalu-
able when attempting to generalize any findings made
in animals to the human condition, the use of recombi-
nant inbreds in the identification of biological
markers may be the most powerful tool currently
available.
This reviewer could find no examples in the literature
where recombinant inbreds have been used to study the
actions of drugs of abuse. This is likely due to the
fact that such animals are not readily available.
However, Dr. Ben Taylor at Jackson Laboratories has
developed a number of recombinant inbred mouse
strains. The value of these animals in drug abuse
related research could prove to be considerable, not
just for the search for biological markers, but also
in any experiment that attempts to assess the rela-
tionship between two or more behavioral, biochemical,
or physiological traits.
Selectively Bred Lines
Selective breeding involves a systematic attempt to
develop an animal with a specific trait. Unlike in-
breeding, selective breeding is directional. Thus,
the probability that two traits will be found in
association with one another by chance in selectively
bred stocks is diminished. Selective breeding will be
successful only if the foundation stock displays
genetically determined variation in the trait of in-
terest. If this is the case, mating of extremes in
the population (i.e., mating the highest with the
highest and the lowest with the 1owest) will result in a
change in the mean value within the selected popula-
tions. If selection is accompanied by outbreeding,
the problems associated with inbreeding are minimized;
i.e., the high line(s) and the low line(s) will become
similar genetically only at those genetic loci that
affect the trait of interest. After approximately 20
generations of selective breeding, the high line will
be homozygous at all of the genetic loci that contri-
bute to a high value while the low line will be homo-
zygous at all the loci that contribute to a low value
of the trait of interest. Assuming that outbreeding
has been maintained, the lines will exhibit the same
diversity at all other genetic loci as existed in the
founding population.
The founding population used to develop selected lines
is extremely critical. The best population to use
would be one that has maximum genetic diversity. Such
a stock, usually referred to as a heterogeneous stock,
can be developed by systematically breeding together
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inbred strains. The best examples of such a stock are
the HS mouse stock that is available at the University
of Colorado Institute for Behavioral Genetics
(McClearn 1972) and the National Institutes of Health
heterogeneous stock rat strain (Hansen and Spuhler
1984). These stocks were derived by systematically
breeding together eight inbred mouse or rat strains.
Therefore, these stocks have considerable genetic
diversity and the likelihood of identifying important
genes or gene products is maximized. If a hetero-
geneous stock is not available, an F3 generation
derived from two inbreds that differ maximally in the
trait of interest may be suitable.
Selective breeding has been used successfully in a
number of areas related to alcoholism. For example, a
number of stocks have been developed that differ in
alcohol preference (Hardones et al. 1950; Eriksson
1968; Li et al., this monograph). Most of these
stocks were obtained by selectively breeding two lines
that differ in free-choice ethanol consumption.
Selectively bred lines of animals have also been ob-
tained that differ in acute sensitivity to ethanol
(McClearn and Kakihana 1981; Riley et al. 1977). One
of these selections, that of McClearn and Kakihana
(1981). involved the development of two lines of mice
--Long-Sleep (LS) and Short-Sleep (SS)—that differ
in duration of ethanol-induced anesthesia (sleep
time). Riley et al. (1977) successfully selected two
rat lines, Most Affected and Least Affected, that
differ in the effect of ethanol on motor activity.
Others (Goldstein and Kakihana 1975; McClearn et al.
1982) have developed mouse lines that differ in dura-
tion or intensity of a withdrawal syndrome following
chronic ethanol treatment. Al though these various
lines have served as valuable tools in testing hy-
potheses that may explain the differing phenotypes,
these animals have not been used in a systematic
search for biological markers of alcoholism.
Unfortunately, very few investigators have used the
selective breeding approach to study drugs of abuse.
The only selection that this reviewer is aware of
involving a drug of abuse involves morphine. Nichols
and Hsiao (1967) selectively bred for high and low
consumption of, or preference for, morphine after the
rats had been chronically treated with morphine and
withdrawn. This selection was quits successful in
that a fourfold difference in consumption of morphine
was detected as early as the third selected genera-
tion. Judson and Goldstein (1978) carried out an
abbreviated selection study in Swiss Webster mice
where lines that differed in levorphanol-induced
alterations in motor activity were sought. After
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three generations, a 3.5-fold difference between the
high (runner) and low (nonrunner) lines was evident.
More recently, Belknap et al. (1983) have reported
their success in developing two lines of mice that
differ in morphine-induced analgesia as measured with
the hot-plate test. This selection is still under-
ray. As of the fourth selected generation, complete
divergence of the high and low analgesia lines has not
been attained. Nonetheless, the high and low lines
differ to a greater degree than do any of the inbred
mouse strains that have been tested. Therefore, it
seems reasonable to suggest that such animals would be
invaluable in the identification of reasons for dif-
ferences in sensitivity to morphine as well as in the
identification of potential biological markers.
Selection processes also may be invaluable in identi-
fying pleiotropic genes. An example that validates
this assertion comes from the work of DeFries et al.
(1978) who selectively bred lines of mice that differ
in open field activity. These lnvestigators selected
duplicate high, low, and control activity mouse lines,
i.e., six separate mouse lines. The foundation stock
was an F3 generation derived from crossing BALB/cJ
mice with C57BL/6J mice. Activity in an open field
arena was measured. Two high lines, two low lines,
and two control (randomly bred) lines were selected
with outbreeding (avoiding common grandparents) being
maintained. The replicate lines avoid or minimize
potential problems associated with breeding of a
finite number of animals. A steady divergence in
activity has been obtained. Interestingly, within 10
to 15 generations, both of the low lines were nearly
100% albino. Apparently, the same gene(s) that in-
fluences coat color (albinism) also regulates loco-
motor activity in an open field arena. Thus, it could
be argued that albinism in the mouse is a biological
marker for a behavioral trait, i.e., low open field
activity. DeFries has argued that low open field
activity may well be an indication of high anxiety.
If so, these mouse stocks could be valuable research
tools for studying anxiety. Even if this is not the
case, the DeFries activity mice provide considerable
support for the notion that biological markers of drug
abuse may be found if appropriate selectively bred
lines are developed.
DISADVANTAGES OF ANIMAL MODELS
While animal models of drug abuse afford a number of
advantages for the identification of biological
markers, a number of potential disadvantages exist.
Perhaps the most important of these is that commonly
used laboratory animal stocks may not have the appro-
priate genome to develop a complete model that mimics
65
in all rays the human condition. It may not be acci-
dental that alcoholism and drug abuse appear to be
uniquely human conditions. Species other than man may
not possess all of the genes required to elicit a full-
blown dependence that resembles the human condition,
Even where more limited aspects of drug dependence are
being studied with animal models, caution must be
taken when extending any potential findings in animals
to humans. It is possible that animals differ in
avidity for alcohol or drugs for reasons that are
inoperative in humans.
Another potential disadvantage of developing animal
models relates to the expense. If recombinant inbreds
or selectively bred lines are to be developed, it will
likely be several years before valuable animals will
be generated. If selected lines are to be used,
special consideration must be given to the selection
phenotype. Unexpected results can sometimes be ob-
tained. For example, we have recently determined that
a very important factor which influences the differ-
ence between the LS and SS mice to an acute dose of
ethanol relates to the fact that these animals were
selected for differences in sleep time following the
intraperitoneal injection of a 30% weight/volume
ethanol solution (Gilliam and Collins 1983); i.e.,
some of the difference in response to ethanol between
the LS and SS lines relates to the fact that the
ethanol was administered via a route that is unimpor-
tant in man. Thus, before selection is even ini-
tiated, the response to be measured, the route of
administration of the drug, and numerous other factors
should be considered carefully. This is especially
the case if the intent of the selection process is to
emulate the human condition.
A number of additional cautions must be considered
when a search for biological markers is undertaken.
The fact that a given gene product seems to be linked
to those genes involved in regulating drug abuse re-
lated behavior in mice or rats is no assurance that
linkage will also be seen in man. If the gene product
of drug abuse genes can be studied in both animals and
man, the chances of correctly identifying a marker
seem greater. The advantage of using animal models
will be greatest if the direct gene products of drug
abuse genes or pleiotropically regulated gene products
can be identified.
CONCLUSIONS
The search for biological markers of drug abuse can be
facilitated by the development of appropriate animal
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models. These models offer the potential for in-
vasive testing as well as the ability to more care-
fully control genotype than is the case in humans.
However, disadvantages exist. These include expense
and the possibility that no animal model will complete-
ly satisfy the requirements needed to mimic the human
condition. Nonetheless, the advantages far outweigh
the disadvantages, particularly when the potential
utility of animal models in answering important mech-
anistic questions regarding drug abuse is considered.
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Genetic Markers of Drug Abuse in
Mouse Models
Louis Shuster, Ph.D.
The brain is a very complex organ. This complexity presents
certain difficulties in the analysis of genetic determinants of
responses to drugs of abuse. One gram of cortical grey matter
contains about 200 million neurons. Each of these makes connec-
tions with several thousand other neurons. A single neuron can
have receptors for several neurotransmitters. Neurons also exhib-
it plasticity--that is, the nature of their neurotransmitters and
receptors can change with time. About 30,000 genes are expressed
specifically by the brain (Sutcliffe and Milner 1984).
These characteristics permit several generalizations about the
genetics of responses to neurotropic drugs. A drug response in-
volves many separate components, such as drug metabolism; neuro-
transmitter turnover; peripheral as well as central responses; and
interactions between several neurotransmitters, brain regions, and
receptors. It is therefore reasonable to assume that a particu-
lar drug response, such as CNS stimulation, can be affected by
many different genes. A corollary assumption is that most of the
mutations that affect such a response will be pleiotropic. For
example, a change in catecholamine metabolism that affects re-
sponsiveness to amphetamine could also alter spontaneous behavior,
cardiovascular responses, etc. Furthermore, the same phenotypic
response, such as increased locomotor activity after a stimulant
drug, could result from mutations at several different loci.
In spite of these complexities, it is nevertheless possible to
distinguish specific mutations that alter various responses to
drugs of abuse. Work with mouse models provides some hope that we
will eventually be able to identify and isolate genetic determi-
nants of drug abuse and link them to known genetic markers.
In the following discussion, it is taken for granted that proof of
a genetic component in drug responses is no longer necessary
(Nebert and Felton 1976). The suitability of the various mouse
models that are available will depend on the aims of any given
research project. These aims can be classified as follows:
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TO PROVIDE A REPRODUCIBLE MODEL OF GENETIC DIFFERENCES
Many inbred lines of mice are readily available from commnercial
suppliers. They were produced by over 20 generations of full-sib
matings and are at least 99.9% homozygous. The simplest way to
look for a strain difference in responses to morphine, cocaine, or
ethanol is to consult Taylor's 1972 genetic similarity matrix.
There is a wide divergence between C57B1/6 and DBA/2, for example.
Several differences have been documented in literature for the
responses of these two strains to narcotics and to ethanol (table
1). Additional differences are described by Oliverio et al.
(1983).
For example, in C57B1/6 but not DBA/2 mice, morphine increases
motor activity, the release of striatal dopamine, and the level of
cyclic AMP in the striatum. DBA/2 mice, on the other hand, show
more analgesia after morphine, sleep three times longer after
ethanol than C57B1/6 mice, and are susceptible to audiogenic
seizures. Exposure to tobacco smoke or the injection of muscimol
increases the motor activity of DBA/2 mice, but decreases the
activity of C57B1/6 mice. There are also striking differences in
voluntary consumption. C57B1/6 mice prefer dilute solutions of
ethanol or morphine to water, but DBA/2 mice do not. Crabbe et
al. (1981) reported that the pituitaries of C57B1/6 mice contain
twice as much beta endorphin as those of DBA/2 mice. Sprott
(1975) has summarized behavioral differences.
Candidate strains can also be selected on the basis of differences
in neurochemical parameters, such as dopamine turnover or norepi-
nephrine content. These may be found in the compilation of Ingram
and Corfman (1980). Mendelian analysis of differences in narcotic
responses can be carried out by making appropriate crosses and
backcrosses. Such crosses have demonstrated, for instance, that
the stimulation of motor activity by morphine behaves as an auto-
somal dominant trait (Castellano and Oliverio 1975). Comparisons
of C57B1/6 and DBA/2 mice have also permitted some correlations
between morphine responses and striatal dopamine activity (Racagni
et al. 1979). In general, inbred lines provide readily available
and consistently reproducible models of high responders and low
responders. However, these lines differ in thousands of genetic
loci and cannot easily be used to establish linkage or to isolate
the determinants which control drug responses.
TO ESTABLISH LINKAGE
Bailey (1971) developed homozygous inbred lines from the F2
generation of crosses between two inbred strains. These recom-
binant-inbred (RI) lines provide a replicable sampling of progen-
itor genes in fixed combinations. Linkage markers are provided by
histocompatibility testing of the RI lines and accessory congenic
lines. The advantage of using RI lines is that extensive breeding
is not required to establish linkage. However, they are most use-
ful when the trait in question is under the control of a single
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TABLE 1
Some Neuropharmacological Differences
Between C57BL/6 AND DBA/2 Mice
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TABLE 1 (continued)
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gene (Taylor 1978). Table 2 lists some RI analyses of responses
to drugs of abuse. In most cases, the establishment of linkage
has not been possible because multiple genes are involved.
One interesting benefit of testing RI lines has been the discovery
of one line, CXBK, that is characterized by a low analgesic re-
sponse to morphine and a decreased number of narcotic receptors in
the brain (Baran et al. 1975). These mice also have a low anal-
gesic response to acupuncture (Pomeranz 1978). to the injection of
D-amino acids (Cheng and Pomeranz 1979). and to stress (Miczek et
al. 1982).
Congenic lines can also be used to establish linkage. These are
developed by repeated backcrossing to one progenitor strain from
the F1 generation until homozygosity is achieved (Bailey 1975).
The resulting lines have a very small portion of parental genome
A. defined by histocompatibility testing, associated with the
other parental genome B. If a congenic line which is over 99.9%
congenic with parent B responds to a drug like parent A, then one
can establish the linkage of that drug response to a defined por-
tion of a particular A chromosome. Successful application of this
approach to drugs of abuse has not yet been reported.
TO ISOLATE GENETIC DETERMINANTS
Selective Breeding
For careful genetic analysis of mechanisms of drug action, one
would like to have two populations of animals which differ only in
a single genetic determinant that controls a particular drug re-
sponse. Selective breeding should, in theory, isolate those genes
which control the selected drug response. The foundation stock
should be genetically diverse. If necessary, such diversity can
be achieved by interbreeding up to eight inbred lines, as was done
in the selection of Long-Sleep (LS) and Short-Sleep (SS) mice for
differential responses to ethanol (McClearn and Anderson 1979).
The importance of carrying replicate lines and keeping stocks
large enough to prevent inbreeding has been emphasized by Crabbe
et al. (1983). They are developing lines that differ in the
intensity of withdrawal after ethanol. Interesting correlations
have been drawn between genetic susceptibility to the depressant
effects of ethanol and the ability of ethanol to fluidize neuronal
membranes (Goldstein et al. 1982). However, selective breeding is
not without problems. Achieving homozygosity is slow and tedious.
Until homozygosity is reached, it is almost impossible to repli-
cate experiments, because the genotypes are continually changing.
The drug tests upon which selection is based are likely to pick up
pleiotropic genes which can affect the responses to a variety of
CNS-active agents. For instance, the LS and SS lines also differ
in their responses to barbiturates, adenosine derivatives, and
other CNS depressants (Dudek et al. 1984;
Proctor and Dunwiddie 1984).
Howerton et al. 1983;
Selective breeding for sensitivity
to anesthesia by nitrous oxide has also revealed a lack of
specificity (Koblin et al. 1984).
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TABLE 2
The Use of Recombinant-Inbred Strains in
Genetic Analysis of Some Drug Responses
Drug Response Conclusion Reference
Scopolamine Exploratory behavior
al. 1974
Oliverio et
al. 1973
One locus on chromosome
4 controlling
exploratory behavior.
plus one on chromosome
17 determining response
to scopolamine
Chlorpromazine Exploratory behavior Two controlling genes, Castellano et
one on chromosome 9
Ethanol Motor activity
Morphine
analgesia
Morphine
hot plate
Motor activity
Morphine Tall-flick analgesia
Morphine Motor activity
Morphine
Naloxone
Sensitization of
motor response
Binding to narcotic
receptors
Opioids
Withdrawal jumping
Binding to brain
membranes
Oxotremorine Hypothermia
gene
Cocaine Liver damage
d-Amphetamine In vivo metabolism
Recessive allele
Eam on chromosome 7
determines marked
decline in activity
More than 2 loci
Bore than 2 loci
2 or more loci
no linkage
2 or more loci
no linkage
no linkage
Two or more genes
controlling
number of receptors
Multiple determinants
Multiple genes
Single controlling
Multiple genes
Multiple genes
Oliverio and
Eleftheriou
1976
Oliverio et
al. 1975
Oliverio et
al. 1975
Shuster et al.
1975
Shuster et al.
1975
Shuster 1975
Baran et al.
1975
Shuster 1984
Reith et al.
1981; Jacob et
al. 1983
Lush and
Andrews 1978
Shuster 1984
Shuster 1984
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Defined Mutants
Hundreds of mutants of inbred mouse lines such as C57B1/6 are
available commercially and, in most cases, the locus Involved has
been established (Green 1981). Screening of these strains for
their responses to drugs of abuse would be a fairly easy way to
isolate genetic determinants. Of course, these genes would have
to be pleiotropic because most of the mutants were first identi-
fied by a change in coat color or some other descriptive pheno-
type l Preliminary work by Katz and Doyle (1980) and by our
laboratory (Shuster 1984) has turned up four mutants of C57B1/6
that differ in one or more responses to morphine (table 3). It is
intriguing that each of these mutations is found on a different
chromosome.
There are other mutants, such as Jimpy, that involve defective
development of the CNS (Law et al. 1978). These can differ in
their responses to morphine, but the defects in the CNS are so
widespread that these mice are not likely to be useful for
studying mechanisms of action.
Sublines
Sublines of several inbred lines have developed as a result of
genetic drift between isolated stocks. The number of gene
differences can be calculated from the number of generations of
inbreeding that took place before and after the stocks were
separated (Bailey 1978). For example, the difference between the
Jackson (J) and Bailey (By) sublines of C57B1/6 is no more than 50
gene pairs. It is extremely Improbable that more than one of
these pairs affects the response to morphine. We have found that
the By subline displays more analgesia after morphine than the J
subline. Crosses and backcrosses have shown that this trait be-
haves as an autosanal dominant gene (Shuster 1984). Assay of nar-
cotic receptors in the brain has revealed a greater number of mu
receptors in the By mice, but no difference in delta or kappa re-
ceptors (Cremins and Shuster 1982). There are no obvious differ-
ences in the appearance of the two sublines. However, given the
nature of genes controlling drug responses, It is not surprising
that pleiotropic characteristics have been distinguished; e.g., By
runs more than J after morphine (Shuster 1984). Also, there are
differences in the climbing responseto apomorphine and the running
after amphetamine (table 4). Other sublines that have not been
studied extensively should also provide useful material for
investigating genetic determinants of drugs of abuse. For
instance, the Jackson subline of BALB/c differs from the NIH,
Bailey, and Texas sublines in that unrelated males of the J
subline will fight viciously when housed together. There Is a
marked difference in the enzymes of catecholamine metabolism
(Ciaranello et al. 1974) and in the sensitivity to d-amphetamine
and ethanol (Moisset 1977, 1978). Here is another Instance of a
single pleiotropic gene affecting several drug responses.
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TABLE 3
Responses of C57Bl/6J and Some Defined Mutants to Morphine
TABLE 4
Some Differences in Drug and Stress Responses Between
the Bailey and Jackson Sublines of C57B1/6 Mice
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TO DERIVE NEW GENETIC MODELS
New methodologies in genetic engineering hold promise for more
rapid development of new mouse strains that could be very useful
for the study of drugs of abuse. For example, once partheno-
genesis has been achieved as a reproducible technique in mice,
both selective breeding and the development of new RI lines could
be carried out much more rapidly because homozygosity could be
achieved in only three or four generations (Csanyi 1984). Gyno-
genesis--that is, the production of diploid offspring from the
fertilization of eggs with inactivated sperm cells followed by
inhibition of the first mitotic division--has been carried out in
fish, frogs, and newts (Csanyi 1984). Hoppe and Illmensee (1977)
claimed to have produced gynogenic mice by cellular surgery, but
their findings have apparently not been replicated in other lab-
oratories (Anonymous 1984).
The pioneering work of Mintz (1978) provides an interesting new
method for producing defined mouse mutants. Teratoma cells, cul-
tured in vivo or in vitro, are integrated with embryonic cells of
a different strain in order to produce a chimera. If the chi-
mera's germ cells are derived from the teratoma, the chimera can
give birth to mice bearing the teratoma genes, These mice do not
develop tumors. Cultured teratoma cells can be exposed to muta-
gens and the mutants can then be selected. Mintz has used this
technique to make a mouse model of hypoxanthine-guanine phosphori-
hosyltransferase deficiency (1978). Application of this
technique to drugs of abuse raises the problem of which responses
can be used in screening. Any tolerance or physical dependence
produced in vitro is unlikely to be a function of genes that are
specifically expressed in the CNS. However, it is conceivable
that mutations affecting the structure and function of cellular
membranes in general would be characterized by altered responses
to ethanol and, perhaps, other drugs as well.
TO STUDY THE ROLE OF ENDOGENOUS OPIOIDS
There is considerable indirect evidence that the release of endog-
enous opioids plays an important role in many forms of stress-
induced analgesia (SIA). We have found important strain and sub-
line-differences in defeat-induced analgesia (Shuster 1984). Re-
peated defeat produces tolerance and cross-tolerance to morphine
analgesia. Furthermore, tolerant animals exhibit withdrawal jump-
ing when injected with naloxone, i.e., they are physically de-
pendent (Shuster et al. 1983). A similar phenomenon has been re-
ported (Christie and Chesher 1982) when mice are stressed by being
forced to swim.
These observations suggest that suitable mouse models could be
identified to test the hypothesis that repeated stress may produce
a craving for drugs of abuse. They also indicate the potential
value of testing drugs of abuse in strains of mice with different
genetically determined patterns of behavior.
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RECOMMENDATIONS FOR FUTURE WORK
It is clear from the foregoing survey that mouse models can pro-
vide very useful genetic tools for studying the actions of drugs
of abuse. However, only a small fraction of the potentially use-
ful material has even been surveyed for drug responses. It would
be most helpful if NIDA could support the following initiatives:
1.
2.
3.
4.
5.
6.
Publication of a compilation of the known responses of in-
bred and recombinant-inbred strains, sublines, and mutants
to drugs of abuse, including ethanol. This information is
scattered through the literature. A compilation would make
it much easier for researchers to choose appropriate models
for testing hypotheses about drug abuse.
A systematic survey of drug responses in currently available
strains and mutants which have not yet been tested. Perhaps
such a survey could be carried out on a contract basis. Of
the 500 or so known single gene mouse mutants, only about 15
have been examined even superficially.
Selective breeding for such parameters as voluntary consump-
tion of ethanol and other drugs of abuse and ethanol. A
good example is the selective breeding of strains of rats
showing high and low preference for ethanol solutions (Li,
this volume). A genetic model for self-administration of
such stimulants as cocaine and amphetamine would be very
helpful.
The development of new recombinant inbred lines to be used
for genetic analysis. This development, like selective
breeding, is a slow and tedious process that is not easy to
support from short-term funding. If it could be carried out
at NIDA, important new resources could be made available to
the research community.
Increased emphasis on genetic correlations between behavior-
al parameters that can involve endogenous opioids and re-
sponses to drugs of abuse. These could include stress-
induced analgesia, aggression, diurnal changes in activity
and pain responses, etc. Also, the effect of stress and
other pretreatments on voluntary consumption should be
examined.
The selection of teratocarcinoma-derived mutants that differ
in their susceptibility to drugs of abuse and/or neuro-
chemical parameters, such as narcotic receptors, opioid pep-
tides, and neurohormone turnover.
REFERENCES
Anonymous. Illmensee inquiry. Nature 308:394, 1984.
Baer, D.S.; McClearn, G.E.; and Wilson, J.R. Effects of chronic
administration of tobacco smoke to mice: Behavioral and meta-
bolic measures. Psychopharmacology 67:131-137, 1980.
80
Bailey, D.W. Recombinant inbred strains. Transplantation
11:325-327, 1971.
Bailey, D.W. Genetics of histocompatibility in mice. I. New loci
and congenic lines. Immunogenetics 2:249-256, 1975. 
Bailey, D.W. Sources of subline divergence and their relative
importance for sublines of six major inbred strains of mice.
In: Morse, H.C., III, ed. Origins of Inbred Mice. New York:
Academic Press, 1978.
Baran, A.; Shuster, L.; Eleftherfou, B.E.; and Bailey, D.W. Opi-
ate receptors in mice. Genetic differences. Life Sci 17:633-
640, 1975.
Brase, D.; Loh, H.H.; and Way, E.L. Comparison of the effects of
morphine on locomotor activity, analgesia and primary and pro-
tracted physical dependence in six mouse strains. J Pharmacol
Exp Ther 201:368-374, 1977.
Castellano, C. Strain-dependent effects of naloxone on discrimi-
nation learning in mice. Psychopharmacoloqy 73:152-156, 1981a.
Castellano, C. Strain-dependent effects of the enkephalin ana-
logue FK33-824 on locomotor activity in mice. Pharmacol
Biochem Behav 15:729-734, 1981b.
Castellano, C., and Oliverio, A. A genetic analysis of morphine-
induced running and analgesia in the mouse. Psychopharmacology
41:197-200, 1975.
Castellano, C., and Puglisi-Allegra, S. Effects of naloxone and
naltrexone on locomotor activity in C57B1/6 and DBA/2 mice.
Pharmacol Biochem Behav 16:561-563, 1982.
Castellano, C.; Eleftheriou, B.E.; Bailey, D.W.; and Oliverio, A.
Chlorpromazine and avoidance behavior: A genetic analysis.
Psychopharmacologia 34:309-316, 1974.
Cheng, R.S.S., and Pomeranz, B. Correlation of genetic differ-
ences in endorphin systems with analgesic effects of D-amino
acids in mice. Brain Res 177:583-587, 1979.
Christie, M.J., and Chesher, G.B. Physical dependence on physio-
logically released endogenous opiates. Life Sci 30:1173-1177,
1982.
Ciaranello, R.D.; Hoffman, H.J.; Shire, J.G.M.; and Axelrod, J.
Genetic regulation of catecholamine biosynthetic enzymes. II.
Inheritance of tyrosine hydroxylase, dopamine hydroxylase and
phenylethanolamine methyl transferase. J Biol Chem 249:4520-
4536, 1974.
Crabbe, J.C., Jr.; Allen, R.G.; Gaudette, N.D.; Young, E.;
Kosobud, A.; and Stack, J. Strain differences in pituitary-
endorphin and ACTH content in inbred mice. Brain Res 219:219-
223, 1981.
Crabbe, J.C.; Kosobud, A.; and Young, E.R. Genetic selection for
ethanol withdrawal severity: Differences in replicate mouse
lines. Life Sci 33:955-962, 1983.
Cremins, J., and Shuster, L. A genetically controlled difference
in morphine analgesia and narcotic receptors in mice. Fed Proc
41:1314. 1982.
Csanyi, V.  Neurochemical genetics.  Int Rev Neurobiol 25:361-389,
1984.
Dudek, B.C.; Abbott, M.E.; and Phillips, T.J. Stimulant and de-
pressant properties of sedative-hypnotics in mice selectively
81
bred for differential sensitivity to ethanol. Psychopharma-
cology 82.46-51 1984.
Ebel, A.; Durkin, T.; Ayad, G.; Mack, G.; and Handel P. Geneti-
cally determined cholinergic involvement in morphine-induced
behavioral responses in mice.
1980.
J Neuropharmacol 19:423-427,
Filibeck, U.; Castellano, C.; and Oliverio, A. Differential
effects of opiate agonists-antagonists on morphine-induced
hyperexcitability and analgesia in mice.
73:134-136, 1981.
Psychopharmacology
Goldstein. D.B.; Chin, J.H.; and Lyon, R.C. Ethanol disordering
of spin-labeled mouse brain membranes: Correlation with
genetically determined ethanol sensitivity of mice. Proc Nat
Acad Sci USA 79:4231-4233, 1982.
Green, M.C. Genetic Variants and Strains of the Laboratory Mouse.
Stuttgart: Gustav Fischer Verlag, 1981.
Gwynn, G.J., and Domino, E.F. Genotype-dependent behavioral
sensitivity to mu vs. kappa opiate agonists. II. Antinocicep-
tive tolerance and physical dependence. J Pharmacol Exp Ther
231:312-316, 1984.
Hill, R.N.; Clemens, T.L.; Liu, D.K.; Vessel, E.S.; and Johnson,
W.D. Genetic control of chloroform toxicity in mice. Science
190:159-161, 1975.
Hoppe, P.C., and Illmensee, K. Microsurgically produced homo-
zygous-diploid uniparental mice. Proc Nat Acad Sci USA
74:5657-5661, 1977.
Horowitz, G.P.; Whitney, G.; Smith, J.C.; and Stephan, F.K.
Morphine ingestion: Genetic control in mice. Psychopharmacol
52:119-122, 1977.
Howerton, T.C.; O'Connor, M.F.; and Collins, A.C. Lipid solubil-
ity is correlated with hypnotic and hypothermic responses of
Long-Sleep (LS) and Short-Sleep (SS) mice to various depressant
drugs. J Pharmacol Exp Ther 227:389-393, 1983.
Ingram, D.K., and Corfman, T.P. An overview of neurobiological
comparisons in mouse strains. Neurosci Biobehav Rev 4:421-435,
1980.
Jacob, J.; Michaud, G.; Nicola, W.A.; and Prudhomme, N. Genetic
differences in opioid binding sites and in antinociceptive
activities of morphine and ethylketocyclatocine. Life Sci
33(Supp. 1):645-648, 1983.
Katz, R.J. The albino locus produces abnormal responses to
opiates in the mouse. Eur J Pharmacol 68:229-232. 1980.
Katz, R.J., and Doyle, Enhanced responses to opiates pro-
duced by a single gene substitution in the mouse. Eur J
Pharmacol 67:301-303, 1980.
Kiianmaa, K., and Tabakoff, B. Neurochemical correlates of toler-
ance and strain differences in the neurochemical effects of
ethanol. Pharmacol Biochem Behav 18(Supp. 1):383-388, 1983.
Koblin, D.D.; Lurz, F.W.; O'Connor, B.; Nelson, N.T.; Eger, E.I.,
II; and Bainton, C.R. Potencies of barbiturates in mice
selectively bred for resistance or susceptibility to nitrous
oxide anesthesia. Anesth Anal 63:35-39, 1984.
Law, P.Y.; Harris, R.A.; Loh, H.H.; and Way, E.L. Evidence for
the involvement of cerebroside sulfate in opiate receptor bind-
82
ing: Studies with Azure A
Exp Ther 207:458-468, 1978.
Lush, I.E., and Andrews, K.M. Genetical differences in sensitivi-
and Jimpy mutant mice. J Pharmacol
ty to tremorine and oxotremorine in mice. Eur J Pharmacol
49:95-103, 1978.
Marks, M.J.; Burch, J.B.; and Collins, A.C. Genetics of nicotine
response in four inbred strains of mice. J Pharmacol Exp Ther
226:291-301. 1983.
McClearn, G.E.; and Anderson, S.M. Genetics and ethanol toler-
ance. Drug Alcohol Depend 4:61-76, 1979.
Miczek, K.A.; Thompson, M.L.; and Shuster, L. Opioid-like
analgesia in defeated mice.
Mintz, B. Gene expression in neoplasia and differentiation.
Harvey Society Lectures, Series 71. New York: Academic Press,
1978. pp 193-245.
Moisset, B. Genetic analysis of the behavioral response to d-am-
phetamine in mice. Psychopharmacology 53:263-267, 1977.
Moisset, B. Sub1ine differences in behavioral responses to
pharmacological agents. In: Horse, H.C., III, ed. Origins of
Inbred Mice. New York: Academic Press, 1978. pp. 483-484.
Muraki, T.; Uzumaki, H.; and Kato, R. Strain difference in
morphine-induced increase in plasma cyclic AMP and cyclic GMP
levels in relation to locomotor activity in male mice. Psycho-
pharmacology 76:316-319, 1982.
Nabeshima, T., and Ho, I.K. Pharmacological responses to pento-
barbital in different strains of mice. J Pharmacol EXp Ther
216:198-204. 1980.
Nebert, D.W., and Felton. J.S. Importance of genetic factors in-
fluencing the metabolism of foreign compounds. Fed Proc
35:1133-1141. 1976.
Oliverio, A., and Castellano, C. Genotype-dependent sensitivity
and tolerance to morphine and heroin: Dissociation between
opiate-induced running and analgesia in the mouse. Psycho-
pharmacology 39:13-22, 1974.
0liverio, A., and Eleftheriou,  B.E. Motor activity and alcohol:
Genetic analysis in the mouse:
1976.
Physiol Behav. 16:577-581,
Oliverio. A.; Eleftheriou, B.E.; and Bailey, D.W. Exploratory
activity: Genetic analysis of its modifications by scopolamine
and amphetamine. Physiol Behav. lO:893-899, 1973.
Oliverio, A.; Castellano, C.; and Eleftheriou, B.E. Morphine sen-
sitivity and tolerance. A genetic investigation in the mouse.
Psychopharmacologia 42:219-224, 1975.
Oliverio, A.; Castellano, C.; and Puglisi-Allegra, S. Psycho-
pharmaco-genetics of opioids. Trends in Pharmacol Sci 4:350-
352, 1983.
Pomeranz, B. Do endorphins mediate acupuncture analgesia? Adv
Biochem Psychopharm l8:351-360 1978.
Proctor, W.R., and Dunwiddie, T.W. Behavioral sensitivity to
purinergic drugs parallels ethanol sensitivity in selectively
bred mice.
Racagni, G.;
Science 224:519-521, 1984.
Bruno, F.; Juliano, E.; and Paoletti, R. Differen-
tial sensitivity to morphine-induced analgesia and motor activ-
ity in two inbred strains of mice: Behavioral and biochemical
83
correlations, J Pharmacol Exp Ther 209:111-116, 1979.
Randt, C.T.; Barnett, B.M.  McEwen, B.S.; and Quatermain, D.
Amnesic effects of cycloheximide on two strains of mice with
different memory characteristics. Exp Neurol 30:467-474, 1971.
Reith, M.E.A.; Sershen, H.; Vadasz, C.; and Lajtha, A. Strain
differences in opiate receptors in mouse brain. Eur J Pharma-
co1 74:377-380, 1981.
Rodgers, D.A. Factors underlying differences in alcohol prefer-
ence among inbred strains of mice. Psychosom Med 28:498-513,
1966.
Shuster, L. Genetic determinants of responses to drugs of abuse:
An evaluation of research strategies. In: Sharp, C.W., ed.
Mechanisms of Tolerance and Dependence. National Institute on
Drug Abuse Research Monograph 54. DHHS Pub. No. (ADM) 84-1330.
Washington, D.C.: Supt. of Docs., U.S. Govt. Print. Off.,
1984. pp. 50-69.
Shuster, L.; Webster, G.W.; Yu, G.; and Eleftheriou, B.E. A
genetic analysis of the response to morphine in mice:
B.E., ed.. Psychopharmacogenetics. New
1975. pp. 73-97.
York: Plenum Press,
to the brain. In:
Amsterdam: Elsevier
Shuster, L. A pharmacogenetic approach
Leiblich, I., ed. Genetics of the Brain.
Biomedical-Press, l982. pp. 157-176.
Shuster, L. Genetic analysis of morphine effects: Activity,
analgesia, tolerance and sensitization. In: Eleftheriou,
Schlesinger, K., and Sharpless, S.K. Audiogenic seizures and
acoustic priming. In: Eleftheriou, B.E. ed. Psychophar-
macogenetics. New York: Plenum Press, 1975. pp. 383-434.
Analgesia and running. Psychopharmacology 42:249-254, 1975.
Shuster, L.; Thompson, H.L.; Miczek K.A.; and Winslow, J.T.
Tolerance to and withdrawal from the effects of chronic defeat.
Neurosci Abstr 9:135, 1983.
Sorenssen, S.; Palmer. M.; Dunwiddie. T.: and Hoffer, B. Electro-
physiological correlates of ethanol-induced sedation in differ-
entially sensitive lines of mice. Science 210:1143-1145, 1980.
Sprott, R.L. Behavioral characteristics C57Bl/6J, DBA/2J and
B6D2Fl mice which are potentially useful for gerontological
research.
Spuhler, K.; Hoffer, B.; Weiner, N.; and Palmer, M. Evidence for
genetic correlation of hypnotic effects and cerebellar Purkinje
neuron depression in response to ethanol in mice. Pharmacol
Biochem Behavior 17:569-578, 1982.
Sutcliffe. J.G., and Milner. R.J. Brain specific gene expression.
TIBS 5:95-99, 1984.
Taylor B.A. Genetic relationships between inbred strains of
mice. J Heredity 63:83-86, 1972.
Taylor, B.A. Recombinant-inbred strains: Use in gene mapping.
In: Morse, H.C., III, ed.  Origins of Inbred Mice. New York:
Academic Press, 1978.
Van Abeelen, J.H.F., and Boersma, H.J.L.M. A genetically con-
trolled hippocampal transmitter system regulating exploratory
behavior in mice. J Neurogenetics 1:153-158. 1984.
84
ACKNOWLEDGMENTS
The research described here was supported by grants DA-01626 and
DA-01885 from the National Institute on Drug Abuse.
AUTHOR
Louis Shuster, Ph.D.
Department of Biochemistry and Pharmacology
Tufts University School of Medicine
Boston, MA 02111
85
Inheritance of Risk To Develop
Alcoholism
C. Robert Cloninger, M.D.; Soren Sigvardsson, Ph.D.;
Theodore Reich, M.D.; and Michael Bohman, M.D.
When alcoholism is assumed to be a discrete unitary trait, its
inheritance is compatible with multifactorial inheritance
(Cloninger et al. 1978). However, recent findings on ongoing
studies in St. Louis and in Sweden of the inheritance of alcoholism
indicate that alcoholism cannot be considered a homogeneous,
discrete clinical disorder. Our studies indicate that the risk of
alcoholism in the general population and in the relatives of
alcoholics changes between generations, coincident with changes in
social patterns of alcohol consumption. As patterns of exposure
to alcohol change, the expression of underlying risk factors
changes and the individuals at risk change. Our findings with
adoptees have demonstrated the interaction of genetic and
environmental factors in the development of alcoholism and have
also distinguished multiple subtypes of alcoholism that have
distinct genetic and environmental determinants.
Recognition of such gene-environment interaction and etiological
heterogeneity will facilitate the identification of genetic and
biological markers for alcoholism. Especially when social
patterns of alcohol and drug intake change between generations, it
becomes difficult to predict who is at risk and, more
specifically, what is the risk of particular individuals. The
implication is that our studies of biological and genetic risk
factors in alcoholism and, more generally substance abuse, must
take into account changing patterns of consumption and consider
the interaction of biological and social risk factors in the
development of clinical disorder. Thus, we must consider both
familial and nonfamilial influences on biosocial risk factors.
SECULAR TRENDS IN ALCOHOL USE AND ABUSE
There are large group differences in the prevalence of alcoholism
due to sociocultural influences . Both consumption and
complications have varied widely from one historical era to
another and currently vary from country to country, between social
classes, between persons of different occupations, and between men
and women (Cahalan 1970; Goodwin 1976). The significance of this
variation is often ignored in biological and genetic research
which presumes that alcoholism is a homogeneous disease entity
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that is stably inherited from one generation to the next. Often
it is asserted that about 25% of the first-degree relatives of
alcoholics themselves will become alcoholic, with the implicit
assumption or suggestion that this is not much influenced by
secular or local differences in alcohol consumption.
Alcohol consumption per capita in the United States has increased
nearly 50% in the past generation (25 years). Half of the
alcohol drunk by Americans annually is consumed by about 10% of
the population, and the risk of social and medical complications
has increased along with overall consumption. This increased
consumption and complication rate is reflected in findings about
the risk of alcoholism in the general population and in the
relatives of alcoholics. Recent results from our ongoing family
study of alcoholics in St. Louis indicate that the risk of
alcoholism in the general population and in the relatives of
alcoholics is about twice the risk estimated 15 years earlier in
St. Louis (table 1).
TABLE 1
Alcoholism in First-Degree Relatives of White
Alcoholic Probands in St. Louis in 1968 and in 1983
Probands
Sex/Year
Prevalence,
% in General Prevalence of Alcoholic Relatives
Population % of men % of women
Men, 1968 11.4 36.0 6.7
(N=751) (N=111) (N=156)
Men, 1983 28.9 62.7 20.6
(N=1202) (N=319) (N=393)
Women, 1968 2.9
(N=608)
31.6
(N=38)
6.7
(N=60)
Women, 1983 4.3
(N=1802)
61.2 20.9
(N=67) (N=91)
The estimates of the lifetime risk of alcoholism in 1968 were
based on the survey of problem drinking described by Cahalan
(1970). The estimates of the lifetime risk of alcoholism in 1983
is based on the recent report of the Epidemiological Catchment
Area project concerning the St. Louis site by Robins et al.
(1984). Alcoholism was diagnosed in relatives of alcoholic
probands using criteria of Feighner et al. (1972) in a comparable
fashion for both time periods. Both definite and probable
alcoholics, using Feighner et al. criteria, are included so that
87
individuals with multiple social and medical problems are
considered affected in table 1. It is difficult to prefer any
particular diagnostic criteria over others because there is no
work that demonstrates a discrete point of rarity or qualitative
difference between alcoholic and nonalcoholic drinkers, such as
that recently demonstrated for schizophrenia (Cloninger et al.
1985a) or somatoform disorders (Cloninger et al. 1984). In any
case, the same diagnostic criteria were applied in comparable
fashion in the two family studies (Winokur et al. 1970; Cloninger
et al. 1978; Reich et al. 1980). The current pattern of sex
differences is similar to that of 15 years ago: alcoholism is
more common in men than in women, but the risk to relatives is the
same regardless of the sex of the alcoholic proband. However, now
the overall risk of alcoholism is about twice that observed less
than a generation ago.
This difference between generations can also be demonstrated
within our recent family study. This study includes personal
interviews with the family members of 184 hospitalized alcoholics,
129 convicted felons with a history of alcohol abuse, and 47 non-
alcoholic controls. This yielded 1,588 personally interviewed
relatives. The risk of alcoholism in first-degree relatives of
alcoholics, regardless of ascertainment source, decreases from the
sibling generation (61% of brothers) to the parental generation
(47%) even without correction for age (Reich et al. 1980).
GENETIC HETEROGENEITY AND GENE-ENVIRONMENT INTERACTION
Rather than assuming that alcoholism is a homogeneous discrete
clinical disorder and asking whether or not it is heritable, we
have sought to clarify the role of etiological heterogeneity,
variable clinical expression, and the interaction of genetic and
environmental risk factors in the Stockholm Adoption Study
(Cloninger et al. 1981, 1984; Bohman et al. 1981, Bohman et al.
1984; Sigvardsson et al. 1984). The subjects included all 862 men
and 913 women of known paternity who were born out of wedlock in
Stockholm from 1930 to 1949 and adopted by nonrelatives at an
early age. Host of the subjects were separated from their
biological relatives in the first few months of life (average: 4
months), and all had their final placement in the adoptive home
prior to age 3 years (average: 8 months). By Swedish practice at
the time, neither the adoptee nor the adoptive parents were
informed about the identity or behavior of the biological parents.
Extensive data about alcohol abuse, criminality, occupational
status, and medical and social history were obtained for all
adoptees and their biological and adoptive parents from several
registers and medical sources. This includes the records of
Temperance Boards and the National Health Insurance Board system,
which includes local insurance agencies, hospitals, and clinics.
The Temperance Board in each community evaluates reports of
intemperance and then registers and imposes fines when
intemperance is confirmed. It also supervises the treatment of
alcoholics and may order involuntary hospitalization if needed.
Other cases of alcoholism in adoptees were identified by records
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of outpatient and inpatient care. The adoptees ranged in age from
23 to 43 years at the time of last information. The data were
available for the lifetime of all subjects (adoptees and both sets
of parents).
The risk of alcohol abuse in adopted men who had biological
parents registered for alcohol abuse was compared to that in other
adoptees (table 2). Alcohol abuse was significantly higher in the
268 adopted-out sons of biological fathers registered for any
alcohol abuse than in the 571 sons of parents with no registered 
alcohol abuse (22.8% versus 14.7%. X2 = 8.27, P < .01). In
addition, of the 32 adopted-out sons of alcoholic biological
mothers, the percentage of alcohol abusers was twice as high as
for the 571 sons of nonalcoholic parents (28.1% versus 14.7%, x2 =
4.18, P < .05).
The effect of parental alcoholism on adopted women was more
complex (Bohman et al. 1981). The frequency of alcohol abuse was
more than 3 times greater in the 51 adopted-away daughters of
TABLE 2
Inheritance of Susceptibility to Alcohol
Abuse in the Stockholm Adoption Study
Alcohol Abuse in Alcohol Abuse in Adoptees
Biological Parents Sons Daughters
Father Mother N % N %
No No 571 14.7 577 2.8
Yes No 259 22.4 285 3.5
No Yes 23 26.0 29 10.3
Yes Yes 9 33.3 22 9.1
alcoholic mothers than in the 577 daughters of nonalcoholic
parents (9.8% versus 2.8%, x2 = 7.17, P < .01). In contrast, the
excess of alcohol abusers among the 307 daughters of all alcoholic
fathers was not significant (3.5% versus 2.8%). However, further
analysis revealed that there was a twofold excess of alcoholic
women among the 120 adopted-out daughters whose congenital
background was characterized largely by biological fathers who had
single registrations with the Temperance Board and no associated
criminality (6.7% versus 3.0%, x2 = 4.51, P < .05) (Bohman et al.
1981). Fathers with recurrent alcohol abuse or criminality had no
excess of alcoholic daughters.
Social factors influenced the expression of risk for alcohol abuse
and, in particular, the frequency of registrations with the
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Temperance Board. Biological fathers with single registrations
for alcohol abuse did not increase the risk of their sons for
either single or recurrent registrations (table 3). However,
fathers with recurrent registrations had an excess of sons with
either single registrations (11.6% versus 6.6%) or recurrent
registrations (15.7% versus 8.6%). Thus, single registrations for
abuse appear to be an expression of the heritable risk for alcohol
abuse in the sons, but not in the fathers. This inconsistency is
largely explained by differences in the social circumstances of
the biological fathers and their adopted-away sons.
TABLE 3
Registrations for Alcohol Abuse in Biological
Fathers and Their Adopted-Away Sons
Father’s No.
Registrations
Number Registrations in Adopted-Away Sons
Sons % only one % recurrent
none 594 6.6 8.6
only one 96 5.2 9.4
recurrent 172 11.6 15.7
The occupational status of the biological fathers tended to be
lover than that of the adoptive fathers, and the occupational
status of the adoptive father influenced the expression of risk
for developing alcoholism. Table 4 shows the frequency of alcohol
abuse registrations in the sons in relation to the number of
registrations of the biological father and the occupational status
of the adoptive father. Adoptive fathers with unskilled
occupations had more sons with alcohol abuse than other adoptive
fathers. If the adoptive father had a skilled occupation, there
was an increased risk of alcohol abuse (single or recurrent) in
sons of biological fathers with recurrent, but not single,
registrations. In contrast, if the adoptive father had an
unskilled occupation, there was an excess of recurrent alcohol
abuse in sons of biological fathers with either single
registrations (17.2% versus 7.6%, x2 = 3.29, P < .06) or recurrent
registrations (19.0% versus 7.6%, x2 = 8.52, P < .01). Thus,
severity of alcohol abuse is a complex product of biological and
social determinants.
The only significant risk factor about the adoptive parents
themselves was low occupational status of the adoptive father.
Alcohol abuse in the adoptive parents was not associated with a
greater risk of alcohol abuse in the adoptees. Only 13% of the 31
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TABLE 4
Occupational Status of the Adoptive Father and Frequency
of Registrations for Alcohol Abuse in Biological Fathers and
Their Adopted-Away Sons
Adoptive
Father’s
Job
skilled
skilled
skilled
unskilled
unskilled
unskilled
Biological
Father’s
Registered
none
once
recurrent
none
once
recurrent
Number of
Sons
406
67
109
188
29
63
Registration of Sons
% once % recurrent
6.2 7.6
4.5 6.0
12.8** 13.8**
7.4 10.6
6.9 17.2*
9.5 19.0***
* P<.10 compared to 406 low-risk sons
** P<.05 compared to 406 low-risk sons
*** P<.01 compared to 406 low-risk sons
men reared by an alcoholic adoptive parent abused alcohol
themselves compared to 18% of the other 831 sons. only 1 (3.7%)
of the 27 daughters reared by an alcoholic adoptive parent became
an alcohol abuser compared to 3.4% of the other 886 daughters.
Thus, imitation of parental alcohol abuse does not appear to be an
important cause of the familial aggregation of alcoholics.
THREE DISTINCT GENETIC TYPES OF ALCOHOL ABUSERS
By a series of independent tests, we have been able to distinguish
three types of alcohol abusers with distinct clinical features and
different genetic and environmental backgrounds (Bohman et al.
1984). These types have been called milieu-limited alcoholism,
male-limited alcoholism, and antisocial behavior disorder with
alcohol abuse. The clinical picture of men and women in each of
the three types of families is summarized in table 5.
The validation of this typology has proceeded by three steps. The
distinction between milieu-limited and male-limited alcoholism was
first identified by subdividing the male adoptees according to
severity, in accord with earlier clinical work by Kaij (1960).
Among the biological mothers and fathers of mild abusers, there
was an excess of mild abuse, but no criminality. Moderate abusers
had an excess of recurrent alcohol abuse complicated by criminal
behavior in their biological fathers, but no excess of alcohol
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TABLE 5
Description of Three Family Types of Alcohol Abusers
Family Type M e n Women
Milieu-Limited
Male-Limited
Alcoholism
usually mild
adult-onset
no criminality
Alcoholism
recurrent
teenage-onset
alcohol treatment
crime due to abuse
Alcoholism
usually mild
adult-onset
no criminality
Somatization
low frequency
diversiform
Antisocial Criminality Somatization
repeated violence high frequency
untreated abuse hypochondriacal
abuse or crime in their mothers. Severe abusers were heterogene-
ous: most had biological parent backgrounds indistinguishable
from mild abusers, but had more deprived adoptive parent
backgrounds than the mild abusers; other severe abusers had
biological parents with prominent criminal backgrounds.
Environmental variables did not influence the adoptees’ risk of
moderate abuse, which was highly heritable from father to son.
This male-limited group of alcoholic families was distinguished
from others in which both fathers and mothers were at increased
risk for alcoholism and the alcohol abuse was less severe and
unassociated with criminality. The latter group was called
milieu-limited because the sons were not at increased risk for
alcoholism unless they had an adoptive father with low social
status in addition to a biological parent with mild abuse.
The proposed distinction between these two types was first tested
by predictions about the biological parents of alcoholic women.
The biological. parents of the 913 adopted women were classified
according to the typology derived using discriminant analysis of
the men (Cloninger et al. 1981; Bohman et al. 1981). We predicted
that daughters in families of milieu-limited, but not male-
limited, alcoholic parents would be at increased risk for
alcoholism. This prediction was confirmed. This confirmation of
different inheritance patterns in our single large population may
reconcile the apparent discrepancies between earlier adoption
studies which were too small to take such heterogeneity into
account (Cloninger et al. 1985b).
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The women in the families of male-limited alcoholics had no excess
of alcohol abuse, so we evaluated their lifetime medical histories
and records of sick leave disability which are maintained for
nearly all Swedish citizens through their National Health
Insurance Board. We found that 10% of Swedish women account for
half of all sick leave disability, and that these "somatizers" are
characterized by recurrent complaints of headache, backache, and
vague abdominal symptoms from an early age (Sigvardsson et al.
1984). Further work revealed that these somatizers included women
with two distinct clinical disorders that were each highly
heritable but independent of one another: “high frequency”
somatizers who have frequent disability from abdominal, back, and
psychiatric complaints; and "diversiform" somatizers who have leas
frequent, but more diversely distributed, physical complaints and
rare psychiatric complaints (Cloninger et al. 1984). Using this
independently derived classification, we found an excess of women
with diversiform somatization in families of male-limited, but not
milieu-limited, alcoholics (Bohman et al. 1984). This strongly
supported the distinction between the two types of alcoholics
derived from the male sample, and indicated that the same genetic
predisposition had different expressions depending on the sex of
the individual.
High frequency somatization was not associated with either male-
limited or milieu-limited alcoholism. However, the male relatives
of these women were characterized by prominent violent criminal
behavior; they often had multiple registrations for alcohol abuse,
but this seldom required medical or psychiatric treatment (Bohman
et al. 1984). These families appear similar in clinical features
and mode of inheritance to families in which antisocial
personality in men aggregates with Briquet’s syndrome in women,
using diagnostic criteria and subjects from the united States
(Cloninger et al. 1975).
IMPLICATIONS FOR FUTURE RESEARCH
Alcoholism is a complex phenotype that appears to be influenced by
multiple genetic and environmental determinants. In order to
characterize its inheritance, we must take into account changing
social patterns of consumption. Also, distinct familial subtypes
with different patterns of gene-environment interaction need to be
distinguished in order to obtain consistent replicable results.
Our demonstration of genetic heterogeneity in the Stockholm
Adoption Study makes it possible to reconcile the discrepant prior
reports of Roe et al, (1945) and Goodwin et al. (1973). Roe’s
findings are consistent with those observed in our milieu-limited
alcoholics, whereas Goodwin’s findings are similar to our male-
limited alcoholics.
Likewise, prior difficulty in obtaining consistently replicable
results with biological and genetic markers in alcoholics may be
attributed to the etiological heterogeneity we have observed.
Individuals in families with alcoholic women more often have
resting electroencephalograms (EEGs) with little alpha activity
and poorly synchronized wave patterns than do individuals in
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families in which only the men abuse alcohol (Propping et al.
1981). This pattern, called the borderline alpha EEC, is
heritable and shows a dramatic increase in alpha activity in
response to alcohol that is coincident with a pleasant feeling of
calm alertness and tension relief, thereby reinforcing the
tendency to drink alcohol in affected individuals (Propping et al.
1980). These findings are suggestive of an association with
milieu-limited alcoholism, but not male-limited alcoholism. In
contrast, preliminary work in Sweden has demonstrated an
association of low platelet monoamine oxidase activity in male-
limited alcoholism, but not milieu-limited alcoholism
(von Knorring et al., in press). Inconsistent prior findings may
be due to neglect of such clinical and etiological heterogeneity.
Further work is needed to specify and refine explicit diagnostic
criteria for clinical subtypes of alcoholism and to identify the
biological and genetic markers which differentiate these
disorders. Recent advances in recombinant DNA technology
(Cloninger et al. 1983) are leading to rapid increases in our
knowledge of the human chromosome map. Quantitative methods for
pedigree analysis (Reich et al. 1980), improved specification of
clinical subtypes, and improved power to detect linkage when it is
present should allow more rapid and consistent progress than in
the past. High priority should be given to studies of families in
which detailed clinical data can be related to putative biological
and genetic markers.
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Genetic and Biological Markers in
Alcoholism and Drug Abuse
Marc A. Schuckit, M.D.
This chapter reviews a research approach that can be used in
the search for genetic trait markers of a vulnerability toward
substance abuse. Reflecting the pattern of studies in the lit-
erature, emphasis is placed on alcoholism, but the possible ap-
plication of findings to other substances is discussed.
Study of a predisposition toward substance abuse is a complex
undertaking. The human body has 70 trillion potential geno-
types, only 5% to 20% of which are active at any one time, and
there is a long lag between the potential onset of gene expres-
sion and the development of the final clinical oicture which
might be labeled substance misuse (Schuckit 1985a).
The comments offered here begin with discussions of data support-
ing the importance of genetic factors in alcoholism and other
drugs of abuse. I then describe a specific model used in our
laboratory for searching for phenotypic markers associated with
a risk for alcoholism. Finally, I discuss the potential re-
search and clinical implications of these findings and suggest
some future directions for research on vulnerabilities toward
misuse of substances other than alcohol.
GENETIC FACTORS IN ALCOHOLISM
Data generated in the last decade from family, twin, and adop-
tion studies point to the importance of genetic factors in al-
coholism (Schuckit 1984a). Virtually all family studies have
shown the familial nature of alcoholism, while studies of iden-
tical twins have documented a higher concordance rate for alco-
holism than in fraternal twins. Other twin studies point to
genetic control of drinking behavior (Partanen 1966): alcohol
metabolism (Vesell et al. 1971); and some alcohol consequences,
such as cirrhosis and psychoses (Hrubec and Omenn 1981). Half-
sibling and adoption studies document a fourfold increased risk
for alcoholism in the adopted-out sons and daughters of alcohol-
ics separated from their biological parents in infancy and
raised without knowledge of their parents' drinking problem
(Schuckit et al. 1972; Goodwin et al. 1974; Bohman et al. 1981;
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Cloninger et al. 1981). However, being raised by an alcoholic
parent figure, but with no alcoholic biological parent, does not
seem to increase the risk for alcoholism.
Finally, animal studies have demonstrated a genetic influence on
alcohol drinking behavior, central nervous system (CNS) sensiti-
vity to alcohol, and the rate of development of tolerance
(Meisch 1982). Dr. T.K. Li (this volume) has discussed these stud-
ies and the development of alcohol-preferring rats, a potentially
powerful tool for alcohol research.
GENETIC STUDIES IN DRUG ABUSE
Unfortunately, information supporting the genetic influence in
abuse of substances other than alcohol is scarce and available
results are inconsistent. Several scientists have bred rat and
mouse strains for morphine-seeking behavior (Nichols and Hsiao
1967; Ericksson and Kiianma 1971). and there is some evidence
that there may be an overlap in an animal's preference for etha-
nol and morphine or phenobarbital (Sinclair et al. 1973). In
animals, at least, one might therefore be dealing with a prefer-
ence for substances that may cross over from ethanol to barbit-
urates or opiates. This hypothesized interaction is consistent
with clinical observations that potentially lethal overdoses of
ethanol might be reversed by naloxone (Dole et al. 1982).
Human genetic studies in drug abuse are also relatively rare.
Family studies have revealed a trend for preference of similar
types of drugs within families, and monozygotic twins show great-
er similarity for drug preference or response than dizygotic
pairs, although not all researchers agree (Gershon 1980; Tennant
1976; Pederson 1981; Liston et al. 1981).
Although there have not been enough studies of the importance of
genetic factors in substance abuse other than alcohol to draw
even tentative conclusions, there are a number of tools that
might be considered for application in the substance abuse area
at the appropriate time. The next section addresses one model.
A MODEL FOR SEARCHING FOR PHENOTYPIC MARKERS IN ALCOHOLISM
There is now enough data supporting genetic influences in alco-
holism to justify a search for the mechanism by which the in-
creased vulnerability is expressed. One approach uses popula-
tions at elevated risk for the future development of alcoholism,
concentrating on individuals before the actual abuse develops.
These populations have been chosen because of demographic char-
acteristics or because of the presence of close family members
who abused substances (Schuckit 1985a).
Our laboratory is currently using a model for searching for
phenotypic markers that might be associated with the vulnerabil-
ity toward alcoholism. Our approach is based on the assumption
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that alcoholism is probably a polygenic and multifactorial dis-
order. It is likely that a number of different types of genetic
vulnerabilities interact with cultural and social factors, such as
availability of alcohol (including the price of alcohol and dis-
tributing laws) and attitudes toward drinking and drunkenness.
Once alcoholism develops, there may be a different set of factors
that perpetuate ft. As an example, I will discuss the results
from our evaluation of whether the level of acute reaction to al-
cohol might contribute to the predisposition toward alcoholism.
Since sons of alcoholics have a significantly higher risk for
this disorder than sons of nonalcoholics, these men are the focus
of our work. Our sample was drawn from over 1,000 male univer-
sity students and nonacademic staff, aged 21 to 25, who responded
to a yearly mailed survey (Schuckit 1984b; 1985b).
Individuals who were already abusing drugs or alcohol
or who had psychiatric or medical problems were excluded from
study. Of the remainder, sons of alcoholics (family history
positive or FHP) who were themselves drinkers, but without sub-
stance-related major life problems, were identified. For every
FHP man, a family history negative (FHN) control matched on age,
race, religion, sex, educational level, drinking pattern, and
drug-taking history was selected.
In Phase 2 of our study, FHP/FHN matched pairs were individually
invited to the laboratory on three occasions where they drank a
placebo, or 0.75 ml/kg of ethanol, or 1.1 ml/kg of ethanol (the
equivalent of about three and six drinks, respectively) under
standard conditions. Before testing, the drinking history was
reevaluated by interview and through analysis of blood alcohol
concentration (BAC) and a series of blood tests likely to change
during heavy drinking (e.g., gamma glutamyl transferase, mean
corpuscular volume, triglycerides, and uric acid) (Schuckit
1984c). In addition, the subjects' expectations of feelings
after three drinks were measured (Schuckit 1984b). Figure 1
shows BAC over time for 34 FHP and 34 FHN men. The time to peak
BAC and the rate of disappearance of ethanol in the two groups
were virtually identical after both doses. FHPs and FHNs also
indicated virtually identical expectations of how alcohol would
make them feel (Schuckit 1984b).
The actual levels of drug effect and feeling of intoxication ex-
perienced after consuming the beverage during the test sessions
was measured on a 36-point analog scale with 0 indicating no
high feeling at all and 36 indicating the highest possible. As
illustrated in figure 2, subjects receiving a placebo reported a
small increase in perception of an ethanol effect at 60 minutes,
while subjects receiving active ethanol doses reported marked
changes in feelings (Schuckit 1984b). The FHN men, however, re-
ported significantly more intense subjective ethanol effects
than the FHP men after the low dose (0.75 ml/kg). Following the
higher ethanol dose (1.1 ml/kg) (figure 3), the group differen-
ces, while present, were not as marked. Therefore, despite
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FIGURE 1
Mean blood alcohol concentrations (BACs) for 34 matched airs
with positive (close circles) and negative (open circles) family
histories after drinking 0.75 ml/kg of ethanol and 1.1 ml/kg of
ethanol. Bars indicate SEM, and B indicates baseline. From
Schuckit 1984b, Archives of General Psychiatry. Copyright 1984,
American Medical Association.
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FIGURE 2
Mean self-ratings on a 0 to 36 scale for drug effect after place-
bo and after 0.75 ml/kg of ethanol for 23 matched pairs with
positive (close circles) and negative (open circles) family his-
tories. Bars indicate SEM and B Indicates baseline. From
Schuckit 1984b. Archives of General Psychiatry. Copyright 1984,
American Medical Association.
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FIGURE 3
Mean self-ratings on a 0 to 36 scale for drug effect after place-
bo and after 1.1 ml/kg of ethanol for 23 matched pairs with posi-
tive (close circles) and negative (open circles) family histor-
ies. Bars indicate SEM and B indicates baseline. From Schuckit
1984b, Archives of General Psychiatry. Copyright 1984, American
Medical Association.
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identical group BACs, similar expectations of the effects of
ethanol, and similar drinking histories, FHNs expressed more
feelings of drug effects, especially after the lower dose chal-
lenge.
We have also evaluated whether the family groups differed on more
objective measures of the effects of alcohol. For example, each
subject's level of standing steadiness or body sway was evaluated
by asking them to stand with their feet together, eyes open; and
hands at their side. Each person was studied at baseline during
each of the three sessions, and then repeatedly every 30 minutes
or so after drinking the beverage. While there were no group
differences at baseline or following placebo, figure 4 demon-
strates the percent of increase in body sway for the two groups
after the low ethanol dose. The FHNs increased their level of
body sway significantly more than the FHPs, a finding consistent
with the subjective response (Schuckit 1985b). Similar but less
intense group differences were again noted after the 1.1 ml/kg
of ethanol.
Finally, the levels of two hormones known to change after drink-
ing were observed as indirect indicators of the body’s response
to alcohol. Serum levels of prolactin (PRL) increased after
ethanol administration for both family groups, but returned to-
ward and below baseline more rapidly for the FHPs (Schuckit et
al. 1983). Similarly, following the 0.75 ml/kg challenge, plasma
levels of cortisol increased for the FHNs but not for the FHPs:
and overall, levels of this hormone were lower for the FHPs dur-
ing most of the experiment (Schuckit 1984d). While hormone
levels were only measured after a single ethanol dose and defi-
nite conclusions could not be made in the absence of data from
a placebo session, the FHP/FHN differences were significant and
results are consistent with a less intensive reaction to ethanol
for FHPs.
In summary, our laboratory is searching for phenotypic markers
of differences between men at higher and lower risk for alcohol-
ism. Once such markers are identified, the next step will be to
determine their level of genetic control, the actual mechanisms
involved in the phenotypic behaviors, and the level of correla-
tion between the markers and the future development of alcohol-
ism. While the genetic work is in its early stages, one consis-
tent lead involves a decreased reaction to modest doses of etha-
nol in young men at elevated future risk for this disorder. It
is possible that one mechanism of increasing the vulnerability
toward alcoholism might occur through a decreased ability to
feel the effects of low ethanol doses, perhaps making it more
difficult to tell when it is time to stop drinking. The differ-
ences in subjective response between FHPs and FHNs have been re-
plicated in two other laboratories (Mednick 1983; O'Malley and
Maisto, in press).
These comments were offered as a model of a research strategy
that can be used in attempting to identify mediators of a genetic,
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FIGURE 4
Percent increase in body sway or standing steadiness following
0.75 ml/kg of ethanol for 23 matched pairs with positive (close
circles) and negative (open circles) family histories. Bars in-
dicate SEM and B indicates baseline. From Schuckit 1985b,
Archives of General Psychiatry. Copyright 1984, American Medi-
cal Association.
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influence in substance abuse. Perhaps similar approaches can be
adapted to the study of genetics of a vulnerability toward mis-
use of other substances. However, before that can be done, much
work needs to be carried out to establish the importance of genet-
ic factors in the predisposition toward abuse of substances
other than alcohol.
FUTURE RECOMMENDATIONS
The information presented here can be used to help develop guide-
lines for future research in genetics of substance abuse. While
this list is not exhaustive, I have attempted to outline factors
that are worth consideration.
1.
2.
3.
4.
Much work needs to be done to establish whether various
forms of substance abuse are genetically influenced. Only
after the importance of these genetic factors has been es-
tablished should studies of populations at high risk for
substance problems be carried out.
For meaningful research in genetics of substance abuse, it
is important that the definition of abuse of substances be
careful1y considered.
tween (a) use of drugs, (b) temporary and relatively mild
Investigators must distinguish be-
problems associated with occasional drug use, and (c) per-
vasive and persistent problems that might be best termed
substance abuse (Schuckit 1984c). Different genetic factors
may contribute at differing levels of importance to each.
For instance, genetic factors may have nothing to do with
why someone decides to try a substance that is readily avail-
able (such as alcohol or marijuana), genetics might contri-
bute slightly to the risk for occasional problems, and an
entirely different set of genetic factors could have a major
impact on the vulnerability toward more pervasive and per-
sistent problems.
It is possible that different genetic influences might con-
tribute to a vulnerability toward the abuse of alcohol than
those which impact on the abuse of heroin, and these might
be separate from factors involved in a predisposition to-
ward polysubstance abuse.
It is important to distinguish between primary substance
abuse and problems related to substance abuse that occur
only in the midst of other major psychiatric disorders (sec-
ondary substance abuse) (Schuckit 1983, 1984c). For ex-
ample, it is probable that important genetic factors influ-
ence the development of the antisocial personality disorder,
which in turn often is associated with abuse of multiple
substances (Vaillant 1982). Thus, the set of genetic fac-
tors associated with substance abuse in patients with a
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primary antisocial personality disorder could be different
from those associated with substance abuse in primary drug
abusers.
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Recommendations for Future
Research on Genetic and
Biological Markers in Drug Abuse
and Alcoholism
Monique C. Braude, Ph.D., and Helen M. Chao, Ph.D.
It is now generally agreed that genetic predisposition plays an
important role in the development of alcoholism in some
individuals. The participants at the joint NIDA/NIAAA Technical
Review on Genetic and Biological Markers in Drug Abuse and
Alcoholism reported that there is so far little evidence linking
drug abuse to genetic markers. However, the consensus of opinion
was that substance abuse could have a genetic component and, like
alcohol abuse, more than a single gene could be affected, i.e., it
would be polygenic in nature.
The workshop participants were asked to present their ideas for
future research which would build upon the current knowledge base.
Most of the question and answer sessions following the oral
presentation of each paper, as well as most of the discussion
session at the end of the meeting, centered on this issue.
It was recommended that a number of steps be taken by both NIDA and
NIAAA to share knowledge and to plan future collaborations. It was
felt that NIDA should increase its research effort at the
preclinical and clinical levels to remedy the paucity of information
in this field and to determine whether or not genetic predisposition
is a factor in substance abuse.
The following is a synthesis of the highlights of some of their
recommendations; it is not intended as, and should not be considered
to be, an exhaustive list.
1. Development of genetically defined animal models of alcohol and
drug abuse
Much of the empirical base of genetic information related to alcohol
and drug abuse has come from animal studies. Experimental animals
selected by genetic breeding for various responses to alcohol or
drugs are powerful tools for studying biological predisposition.
Several lines of rodents have been successfully bred for alcohol-
drinking behavior and CNS sensitivity to alcohol. Research along
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this avenue should be continued in the alcohol field. Selective
breeding approaches should also be used to develop models to study
drugs of abuse, to obtain genetic stocks of animals that differ in
avidity, in initial sensitivity, tolerance development, and severity
of withdrawal for specific drugs of abuse. The development of
strains of preferring or nonpreferring animals is usually done in
mice or rats (faster and cheaper), but care has to be exercised that
the results in rodents can be extrapolated to higher species. This
is a long-term approach; it requires considerable amounts of money
and expertise, as well as time, but has been very fruitful in the
alcohol field.
2. Studies of the genetic makeup of primates resistant to substance
abuse
A search could be initiated in the various primate studies supported
by NIDA to look for animals which are not vulnerable to substance
abuse and to determine their genetic makeup, i.e., to determine
which animals are protected and what are the limits of that
protection.
3. Screening of inbred strain for differences in the trait of
interest
which may not be directly relevant to the addiction process. NIDA
is already supportin
should add very little cost to the program.
work in this area, and this reorientation
Mice or rat strain differences in response to drugs of abuse have
been reported for a variety of drugs of abuse: alcohol,
amphetamines, barbiturates, hallucinogens, opiates, and others.
Most of these studies have investigated acute responses to drugs,
and a few have looked at drug self-administration or severity of a
withdrawal syndrome. The fact that strain differences have been
identified makes one assume that genetic factors are important in
regulating drug abuse responses in animals and that genetic markers
might be found. The various preclinical studies looking at
different genetic strains should be reoriented towards increased
emphasis to the problems of addiction rather than using as
biological markers other effects such as motor activity or analgesia
4. Adoption and twin studies
Adoption and twin studies have provided strong evidence for genetic
involvement in the development of alcoholism. Well-designed
prospective and longitudinal studies on children of alcoholics
should be continued to study inheritance patterns and predictors of
familial or clinical subtypes of alcoholism. Studies of families in
which detailed clinical data can be correlated to biological and
genetic markers need to be conducted. Attention must be given to
refinement of subtype classification as well as to the contribution
of environmental factors.
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In regard to human studies, it is evident that NIDA's program has
not yet been fully developed. For instance, there is so far only
one small twin study published on the effects of opiates and only
one study supported by NIDA on the genetic correlates of marijuana
use. Population studies such as those conducted by the alcohol
researchers need to be pursued to establish the role of genetics in
addiction behavior.
An increased collaboration between NIDA and NIAAA was recommended,
as some of the human studies could share protocols and populations.
The alcohol researchers attending the meeting mentioned that they
would gladly collaborate with NIDA and could insert in their
questionnaires items relevant to drug abuse, thus making the human
studies less expensive than if initiated by either Institute
separately.
5. Genetic markers directly linked to alcoholism and drug abuse
Such markers need to be studied in order to understand the
relationship between the specific gene and the addiction process.
Studies should be conducted to test major locus effects on
susceptibility to alcohol and drug abuse and to assess the
contribution of identified major gene loci to such risks.
6. Increased clinical-preclinical communication
As in many other areas, the participants strongly recommended that
increased communication be developed between the clinical and
preclinical researchers through joint meetings such as workshops or
seminars, as it is clear that there is a definite lack of active
communication between the clinical and preclinical scientists.
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Vol. 1: GPO out of stock NTIS PB #272 867/AS $34.95
Vol. 2: GPO out of stock NTIS PB #272 868/AS $28.95
2 OPERATIONAL DEFINITIONS IN SOCIO-BEHAVIORAL DRUG USE RESEARCH
1975. Jack Elinson, Ph.D., and David Nurco, Ph.D., eds.
NCDAI out of stock
GPO out of stock NTIS PB #246 338/AS $16.95
3 AMINERGIC HYPOTHESES OF BEHAVIOR: REALITY OR CLICHE? Bruce J.
Bernard, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #246 687/AS $16.95
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4 NARCOTIC ANTAGONISTS: THE SEARCH FOR LONG-ACTING PREPARATIONS.
Robert Willette, Ph.D., ed.
GPO out of stock NTIS PB #247 096/AS $9.95
5 YOUNG MEN AND DRUGS: A NATIONWIDE SURVEY. John A. O'Donnell,
Ph.D., et al. NCDAI out of stock
GPO out of stock NTIS PB #247 446/AS $16.96
6 EFFECTS OF LABELING THE "DRUG ABUSER": AN INQUIRY. Jay R.
Williams, Ph.D. NCDAI out of stock
GPO out of stock NTIS PB #249 092/AS $9.95
7 CANNABINOID ASSAYS IN HUMANS. Robert Willette, Ph.D., ed.
GPO out of stock NCDAI out of stock
NTIS PB #251 905/AS $16.95
8 Rx: 3x/WEEK LAAM - ALTERNATIVE TO METHADONE. Jack Blaine, M.D.,
and Pierre Renault, M.D., eds. NCDAI out of stock
Not available from GPO NTIS PB #253 763/AS $16.95
9 NARCOTIC ANTAGONISTS: NALTREXONE PROGRESS REPORT. Demetrios
Julius, M.D., and Pierre Renault, M.D., eds.
GPO out of stock NCDAI out of stock
NTIS PB #255 833/AS $16.95
10 EPIDEMIOLOGY OF DRUG ABUSE: CURRENT ISSUES. Louise G. Richards,
Ph.D., and Louise B. Blevens, eds. NCDAI out of stock
GPO out of stock NTIS PB #266 691/AS $22.95
11 DRUGS AND DRIVING. Robert Willette, Ph.D., ed.
NCDAI out of stock
GPO Stock #017-024-00576-2 $5.50 NTIS PB #269 602/AS $16.95
12 PSYCHODYNAMICS OF DRUG DEPENDENCE. Jack D. Blaine, M.D., and
Demetrios A. Julius, M.D., eds. NCDAI out of stock
GPO out of stock NTIS PB #276 084/AS $16.95
13 COCAINE: 1977. Robert C. Petersen, Ph.D., and Richard C.
Stillman, M.D., eds. NCDAI out of stock
GPO Stock #017-024-00592-4 $6 NTIS PB #269 175/AS $22.95
14 MARIHUANA RESEARCH FINDINGS: 1976. Robert C. Petersen, Ph.D.,
ed. NCDAI out of stock
GPO out of stock NTIS PB #271 279/AS $22.95
15 REVIEW OF INHALANTS: EUPHORIA TO DYSFUNCTION. Charles Wm. Sharp,
Ph.D., and Mary Lee Brehm, Ph.D., eds.
GPO out of stock NTIS PB #275 798/AS $28.95
16 THE EPIDEMIOLOGY OF HEROIN AND OTHER NARCOTICS. Joan Dunne
Rittenhouse, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #276 357/AS $22.95
113
17 RESEARCH ON SMOKING BEHAVIOR. Murray E. Jarvik, M.D., Ph.D., et
al., eds. NCDAI out of stock
GPO out of stock NTIS PB #276 353/AS $28.95
18 BEHAVIORAL TOLERANCE: RESEARCH AND TREATMENT IMPLICATIONS.
Norman A. Krasnegor, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #276 337/AS $16
19 THE INTERNATIONAL CHALLENGE OF DRUG ABUSE. Robert C. Petersen,
Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #293 807/AS $28.95
20 SELF-ADMINISTRATION OF ABUSED SUBSTANCES: METHODS FOR STUDY.
Norman A. Krasnegor, Ph.D., ed.
GPO out of stock NTIS PB #288 471/AS $22.95
21 PHENCYCLIDINE (PCP) ABUSE: AN APPRAISAL. Robert C. Petersen,
Ph.D., and Richard C. Stillman, M.D., eds.
GPO Stock #017-024-00785-4 $7 NTIS PB #288 472/AS $28.95
22 QUASAR: QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS OF
ANALGESICS, NARCOTIC ANTAGONISTS, AND HALLUCINOGENS. Gene Barnett,
Ph.D.; Milan Trsic, Ph.D.; and Robert Willette. Ph.D.; eds.
GPO out of stock NCDAI out of stock
NTIS PB #292 265/AS $35.50
23 CIGARETTE SMOKING AS A DEPENDENCE PROCESS. Norman A. Krasnegor,
Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-00895-8 $6 NTIS PB #297 721/AS $22.95
24 SYNTHETIC ESTIMATES FOR SMALL AREAS: STATISTICAL WORKSHOP PAPERS
AND DISCUSSIDN. Jos. Steinberg, ed. NCDAI out of stock
GPO out of stock NTIS PB #299 OO9/AS $22.95
25 BEHAVIORAL ANALYSIS AND TREATMENT OF SUBSTANCE ABUSE. Norman A.
Krasnegor, Ph.D., ed.
GPO out of stock NTIS PB #80-112428 $22.95
26 THE BEHAVIORAL ASPECTS OF SMOKING. Norman A. Krasnegor, Ph.D.,
ed. (Reprint from 1979 Surgeon General's Report on Smoking and
Health.)
GPO out of stock NTIS PB #80-118755 $16.95
27 PROBLEMS OF DRUG DEPENDENCE, 1979: PROCEEDINGS OF THE 41ST
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. L.S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-00981-4 $9 NTIS PB #80-175482 $40.95
28 NARCOTIC ANTAGONISTS: NALTREXONE PHARMACOCHEMISTRY AND
SUSTAINED-RELEASE PREPARATIONS. Robert Willette, Ph.D., and
Gene Barnett, Ph.D., eds. NCDAI out of stock
GPO out of stock NTIS PB #81-238875 $22.95
29 DRUG ABUSE DEATHS IN NINE CITIES: A SURVEY REPORT. Louis A.
Gottschalk, M.D., et al. NCDAI out of stock
GPO out of stock NTIS PB #80-178882 $16.95
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30 THEORIES ON DRUG ABUSE: SELECTED CONTEMPORARY PERSPECTIVES. Dan
J. Lettieri, Ph.D.; Mollie Sayers; and Helen W. Pearson, eds.
NCDAI out of stock
GPO Stock #017-024-00997-1 $10 Not available from NTIS
31 MARIJUANA RESEARCH FINDINGS: 1980. Robert C. Petersen, Ph.D.,
ed.
GPO out of stock NTIS PB #80-215171 $22.95
32 GC/MS ASSAYS FOR ABUSED DRUGS IN BODY FLUIDS. Rodger L. Foltz,
Ph.D.; Allison F. Fentiman, Jr., Ph.D.; and Ruth B. Foltz.
GPO out of stock NTIS PB #81-133746 $22.95
33 BENZODIAZEPINES: A REVIEW OF RESEARCH RESULTS, 1980. Stephen I.
Szara. M.D., D.Sc., and Jacqueline P. Ludford, M.S., eds.
GPO Stock #017-024-01108-8 $5 NTIS PB #82-139106 $16.95
34 PROBLEMS OF DRUG DEPENDENCE, 1980: PROCEEDINGS OF THE 42ND
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01061-8 $8 NTIS PB #81-194847 $34.95
35 DEMOGRAPHIC TRENDS AND DRUG ABUSE, 1980-1995. Louise G.
Richards, Ph.D., ed.
GPO out of stock NTIS PB #82-103417 $16.95
36 NEW APPROACHES TO TREATMENT OF CHRONIC PAIN: A REVIEW OF
MULTIDISCIPLINARY PAIN CLINICS AND PAIN CENTERS. Lorenz K.Y.
Ng, M.D., ed.
GPO out of stock NTIS PB #81-240913 $22.95
37 BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE. Travis
Thompson, Ph.D., and Chris E. Johanson, Ph.D., eds.
NCDAI out of stock
GPO Stock #017-024-01109-6 $7 NTIS PB #82-136961 $28.95
38 DRUG ABUSE AND THE AMERICAN ADOLESCENT. Dan J. Lettieri, Ph.D.,-
and Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01107-O $4.50 NTIS PB #82-148198 $16.95
39 YOUNG MN AND DRUGS IN MANHATTAN: A CAUSAL ANALYSIS.
Richard R. Clayton, Ph.D., and Harwin L. Voss, Ph.D.
GPO Stock #017-024-01097-9 $5.50 NTIS PB #82-147372 $22.95
40 ADOLESCENT MARIJUANA ABUSERS AND THEIR FAMILIES. Herbert
Hendin, M.D., Ann Pollinger, Ph.D., Richard Ulman, Ph.D., and
Arthur Carr, Ph.D. NCDAI out of stock
GPO out of stock NTIS PB #82-133117 $16.95
41 PROBLEMS OF DRUG DEPENDENCE, 1981: PROCEEDINGS OF THE 43RD
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
Not available from GPO NTIS PB #82-190760 $40.95
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42 THE ANALYSIS OF CANNABINOIDS IN BIOLOGICAL FLUIDS. Richard L.
Hawks, Ph.D., ed.
GPO Stock #017-024-01151-7 $5 NTIS PB #83-136044 $16.95
43 PROBLEMS OF DRUG DEPENDENCE, 1982: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #83-252-692/AS $40.95
44 MARIJUANA EFFECTS ON THE ENDOCRINE AND REPRODUCTIVE SYSTEMS.
Monique C. Braude, Ph.D., and Jacqueline P. Ludford, M.S., eds. A
RAUS Review Report.
GPO Stock #017-024-01202-5 $4 NTIS PB #85-150563/AS $16.95
45 CONTEMPORARY RESEARCH IN PAIN AND ANALGESIA, 1983. Roger M.
Brown, Ph.D.; Theodore M. Pinkert, M.D., J.D.; and Jacqueline P.
Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01191-6 $2.75 NTIS PB #84-184670/AS $11.95
46 BEHAVIORAL INTERVENTION TECHNIQUES IN DRUG ABUSE TREATMENT. John
Grabowski. Ph.D.; Maxine L. Stitzer. Ph.D., and Jack E.
Henningfield, Ph.D., eds.
GPO Stock #017-024-01192-4 $4.25 NTIS PB #84-184688/AS $16.95
47 PREVENTING ADOLESCENT DRUG ABUSE: INTERVENTION STRATEGIES.
Thomas J. Glynn, Ph.D.; Carl G. Leukefeld, D.S.W.; and
Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01180-1 $5.50 NTIS PB #85-159663/AS $22.95
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING BEHAVIOR.
John Grabowski, Ph.D., and Catherine S. Bell, M.S., eds.
GPO Stock #017-024-01181-9 $4.50 NTIS PB 84-145-184 $16.95
49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 45TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01198-3 $12 NTIS PB 85-151553/AS $34.95
50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMENT OF ABUSE. John
Grabowski, Ph.D., ed.
GPO Stock #017-020-01214-9 $4.50 NTIS PB 85-150381/AS $16.95
51 DRUG ABUSE TREATMET EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims, Ph.D., ed.
GPO Stock #017-020-01218-1 $4.50 NTIS PB 85-150365/AS $16.95
52 TESTING DRUGS FOR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE
LIABILITY. Joseph V. Brady, Ph.D., and Scott E. Lukas, Ph.D., eds.
GPO Stock #017-O24-0204-1  $4.25 NTIS PB 85-150373/AS $16.95
53 PHARMACOLOGICAL ADJUNCTS IN SMOKING CESSATION. John Grabowski,
Ph.D., and Sharon M. Hall, Ph.D., eds.
GPO Stock #017-024-01266-1 $3.50
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54 MECHANISMS OF TOLERANCE AND DEPENDENCE. Charles Wm. Sharp,
Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01213-1 $8.50
55 PROBLEMS OF DRUG DEPENDENCE, 1984. PROCEEDINGS OF THE 46TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed.
GPO Stock #017-024-01242-4 $9.50
56 ETIOLOGY OF DRUG ABUSE: IMPLICATIONS FUR PREVENTION. Coryl LaRue
Jones, Ph.D., and Robert J. Battjes, D.S.W., eds.
GPO Stock #017-024-01250-5 $6.50
57 SELF-REPORT METHODS OF ESTIMATING DRUG USE: MEETING CURRENT
CHALLENGES TO VALIDITY. Beatrice A. Rouse, Ph.D., Nicholas J.
Kozel, M.S., and Louise G. Richards, Ph.D., eds.
GPO Stock #017-024-01246-7 $4.25
58 PROGRESS IN THE DEVELOPMENT OF COST-EFFECTIVE TREATMENT FOR DRUG
ABUSERS. Rebecca S. Ashery, D.S.W., ed.
GPO Stock #017-024-01247-5 $4.25
59 CURRENT RESEARCH ON THE CONSEQUENCES OF MATERNAL DRUG ABUSE.
Theodore M. Pinkert, M.D., J.D., ed.
GPO Stock #017-024-01249-1 $2.50
60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora Chiang,
Ph.D., and Charles C. Lee, Ph.D., eds.
GPO Stock #017-024-01257-2 $3.50
61 COCAINE USE IN AMERICA: EPIDEMIOLOGIC AND CLINICAL PERSPECTIVES.
Nicholas J. Kozel, M.S., and Edgar H. Adams, M.S., eds.
GPO Stock #017-024-01258-1 $5
62 NEUROSCIENCE METHODS IN DRUG ABUSE RESEARCH. Roger M. Brown,
Ph.D., and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01260-2 $3.50
63 PREVENTION RESEARCH: DETERRING DRUG ABUSE AMONG CHILDREN AND
ADOLESCENTS. Catherine S. Bell, M.S., and Robert Battjes,
D.S.W., eds.
GPO Stock #017-024-01263-7 $5.50
64 PHENCYCLIDINE: AN UPDATE. Doris H. Clouet, Ph.D., ed.
GPO Stock #017-024-01281-5 $6.50
IN PRESS
65 WOMEN AND DRUGS: A NEW ERA FOR RESEARCH. Barbara A. Ray, Ph.D.,
and Monique C. Braude, Ph.D., eds.
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